Healthcare

Repligen Corporation, a life sciences company trading under ticker RGEN, completed its purchase of 908 Devices Inc's desktop portfolio of four bioprocessing process analytical technology (PAT) devices on March 4, 2025. The transaction was structured as a securities and asset purchase, with Repligen Corporation and its subsidiary Repligen GmbH (together, the purchasers) acquiring 100 percent of the equity interests of 908 Devices GmbH along with certain other assets and liabilities, collectively comprising 908 Devices' entire desktop business. The disposition was disclosed in a Form 8-K filed by 908 Devices Inc (Nasdaq: MASS, CIK 0001555279) on March 4, 2025, reporting Items 1.01, 2.01, 8.01 and 9.01, with the underlying Securities and Asset Purchase Agreement, dated March 4, 2025, attached as Exhibit 2.1. The products acquired include MAVERICK and MAVEN, used for real-time monitoring and control of critical bioprocess parameters, REBEL, an at-line cell culture media analyzer, and ZipChip, a high-resolution sample separations device used in characterization of product quality attributes (the pro forma financial statements also reference a fifth product, Trace C2, as part of the divested desktop commercial-stage analytical technology devices). Olivier Loeillot, President and CEO of Repligen, said: "We are really excited to onboard the 908 bioprocessing team and the four differentiated upstream PAT technologies that are commercialized today. They are the perfect complement to our downstream analytics portfolio and will enable Repligen to further penetrate a broad set of modalities and offer analytics solutions across the entire bioprocess workflow. This asset acquisition is a true win-win for both organizations, and a significant step forward for Repligen as our customers increasingly embed digitization technologies in their production processes." Kevin J. Knopp, CEO and Co-founder of 908 Devices, stated: "Repligen's leadership in commercializing innovative solutions that advance bioprocessing is a great fit for our novel desktop devices and our bioprocessing team. I wish them continued success. Going forward, 908 Devices will continue to advance chemical detection at the point of need with our handheld analytical devices in vital health and safety applications." The purchase price was $70 million in cash, payable by the purchasers for the transferred equity interests and purchased assets, subject to customary adjustment for working capital. A portion of the purchase price is being held in escrow for a period following closing as a source of recovery for possible indemnification claims or negative purchase price adjustments. Per 908 Devices' pro forma disclosure, the upfront payment amounted to $66.0 million net of approximately $4.0 million of transaction costs. 908 Devices estimated a gain on sale of approximately $54.7 million, calculated as total consideration of roughly $67.2 million (the net upfront payment plus a $1.1 million release of cumulative translation adjustment related to 908 Devices GmbH) less net assets transferred of approximately $12.5 million, consisting primarily of accounts receivable, inventory, property and equipment, operating lease right-of-use assets, and intangible assets net of related deferred tax liabilities, offset by assumed liabilities including accounts payable, accrued expenses, deferred revenue and operating lease liabilities. 908 Devices cautioned that this accounting for the gain was preliminary and subject to revision as further analysis of the acquired assets and assumed liabilities was completed. As part of the agreement, 908 Devices and its subsidiaries agreed to a five-year non-compete covering the divested desktop business and an 18-month restriction on soliciting employees who provided services to that business, while the purchasers agreed to an 18-month non-solicitation covenant with respect to 908 Devices' remaining employees. The parties also entered into a transition services agreement under which 908 Devices will provide certain technology, financial and operational transition services to the purchasers through December 31, 2025, a supply agreement under which 908 Devices will continue to supply certain products related to the divested business, and license/sublicense agreements covering intellectual property used in the divested business that was not transferred. Repligen also assumed the lease for the Desktop Business's North Carolina facility and entered into employment agreements with more than fifty employees of 908 Devices who supported that business; 908 Devices expected to terminate its remaining employees who had supported the Desktop Business, anticipated to occur in March 2025. On the financial advisory side, Centerview Partners LLC acted as financial advisor to Repligen Corporation, and Perella Weinberg Partners acted as financial advisor to 908 Devices Inc. On the legal side, Goodwin Procter served as legal counsel to Repligen Corporation, and Paul Hastings LLP served as legal counsel to 908 Devices Inc. 908 Devices' board of directors approved the disposition. Because the sale did not constitute a disposition of substantially all of 908 Devices' assets, stockholder approval was not required under Delaware law in connection with the transaction. No separate financing or regulatory-approval contingency was disclosed in the filings reviewed; the 8-K reflects that the transaction had already closed on the date it was signed (March 4, 2025). Following the close, 908 Devices began presenting the divested Desktop Business as a discontinued operation effective in the first quarter of 2025. On a pro forma basis giving effect to the sale as if it had occurred January 1, 2024, 908 Devices' continuing-operations revenue for fiscal 2024 was $47.7 million (versus $59.6 million historical total revenue) and its pro forma net loss from continuing operations was $40.4 million, or $1.19 per basic and diluted share (versus a $72.2 million historical net loss, or $2.12 per share). For fiscal 2023, pro forma continuing-operations revenue was $38.2 million (versus $50.2 million historical) and the pro forma net loss from continuing operations was $20.7 million, or $0.64 per share (versus a $36.4 million historical net loss, or $1.13 per share). No contingent consideration, earnout, or seller financing tied to the $70 million headline price was disclosed beyond the working-capital adjustment and indemnification escrow referenced above; the specific size and duration of the escrow were not disclosed in the filings reviewed. No EV/EBITDA, revenue, or other valuation multiple for the transaction was disclosed by either company in the filings reviewed.

Abbott Laboratories, a healthcare sector company trading under the ticker ABT, issued $20 billion in aggregate principal amount of senior notes across eight tranches. The offering priced on February 23, 2026 pursuant to a pricing agreement among Abbott and representatives Morgan Stanley & Co. LLC, Barclays Capital Inc., BofA Securities, Inc. and J.P. Morgan Securities LLC, and closed on March 9, 2026, when Abbott completed the issuance and sale of the notes, according to a Form 8-K filed with the SEC that date. The eight tranches, their principal amounts, coupons and maturities are: Floating Rate Notes due 2029 ($1.0 billion, SOFR plus 0.500%, maturing March 9, 2029); 3.700% Notes due 2029 ($2.25 billion, maturing March 9, 2029); 4.000% Notes due 2031 ($2.5 billion, maturing March 15, 2031); 4.300% Notes due 2033 ($2.75 billion, maturing March 15, 2033); 4.650% Notes due 2036 ($3.75 billion, maturing March 15, 2036); 4.750% Notes due 2038 ($2.0 billion, maturing March 15, 2038); 5.500% Notes due 2056 ($3.75 billion, maturing March 15, 2056); and 5.600% Notes due 2066 ($2.0 billion, maturing March 15, 2066). Settlement for all tranches occurred March 9, 2026. Per the final pricing term sheet (free writing prospectus filed February 24, 2026), the fixed-rate tranches priced at the following prices to public and yields to maturity: the 2029 Notes at 99.873% (yield 3.745%, +30 bps to the benchmark 3.500% Treasury due February 15, 2029); the 2031 Notes at 99.855% (yield 4.032%, +45 bps to the 3.750% Treasury due January 31, 2031); the 2033 Notes at 99.813% (yield 4.331%, +55 bps to the 4.000% Treasury due January 31, 2033); the 2036 Notes at 99.753% (yield 4.681%, +65 bps to the 4.125% Treasury due February 15, 2036); the 2038 Notes at 99.718% (yield 4.781%, +75 bps to the same 2036 benchmark Treasury); the 2056 Notes at 99.882% (yield 5.508%, +80 bps to the 4.625% Treasury due November 15, 2055); and the 2066 Notes at 99.872% (yield 5.608%, +90 bps to the same 2055 benchmark Treasury). The Floating Rate Notes priced at 100.000% of par. Each fixed-rate tranche carries a par call date ranging from one to six months before its stated maturity, after which Abbott may redeem at par plus accrued interest; prior to the par call date, Abbott may redeem at a make-whole price based on the applicable Treasury rate plus a spread of 5 to 15 basis points depending on the tranche. The Floating Rate Notes are not redeemable prior to maturity except via special mandatory redemption. Abbott estimated net proceeds of approximately $19,825,943,100 after underwriting discounts and estimated offering expenses, according to the prospectus supplement. Per-tranche underwriting discounts ranged from 0.250% (Floating Rate Notes and 2029 Notes) up to 0.875% (2056 and 2066 Notes). Abbott stated it intends to use the net proceeds, together with cash on hand and/or additional borrowings (which may include commercial paper issuances), to fund the cash consideration for its acquisition of Exact Sciences Corporation under an Agreement and Plan of Merger dated November 19, 2025 (Abbott, Exact Sciences and Badger Merger Sub I, Inc.), to repay certain existing indebtedness of Exact Sciences, to pay related fees and expenses, and for general corporate purposes, which may include repayment of other indebtedness. The notes are unsecured, unsubordinated obligations ranking equally with Abbott's other unsecured and unsubordinated debt. The notes carry a special mandatory redemption feature: if the Exact Sciences acquisition is not consummated within five business days after the later of February 17, 2027 or any later merger-agreement "End Date," or if Abbott notifies the trustee it will not pursue the acquisition, Abbott must redeem all outstanding notes at 101% of principal plus accrued and unpaid interest to the special mandatory redemption date. The joint book-running managers across all eight tranches were Morgan Stanley, Barclays, BofA Securities and J.P. Morgan. Additional joint book-running managers with tranche-specific roles were BNP Paribas (2031 and 2038 Notes), Citigroup (Floating Rate Notes, 2029 Notes and 2066 Notes), Deutsche Bank Securities (2056 Notes), MUFG (2033 Notes) and Societe Generale (2036 Notes). The senior co-manager tier included Santander, HSBC, RBC Capital Markets, Siebert Williams Shank, BBVA, Mizuho, Academy Securities, U.S. Bancorp, Goldman Sachs, Standard Chartered Bank and ING, generally covering all or multiple tranches. The notes were issued under an existing indenture dated March 10, 2015 between Abbott and U.S. Bank National Association, as supplemented by an officers' certificate dated March 9, 2026. For legal counsel, the prospectus supplement states that certain legal matters in connection with the offering were passed upon for Abbott by Wachtell, Lipton, Rosen & Katz, New York, and for the underwriters by Davis Polk & Wardwell LLP, New York. No credit rating agency names (Moody's, S&P or Fitch) or specific assigned ratings appear in the prospectus supplement, the pricing term sheet, or either Form 8-K reviewed. As disclosed, the notes are not listed on any national securities exchange and there is currently no public trading market for them.

AbbVie Inc., a healthcare sector company trading under the ticker ABBV, is undertaking a debt capital markets transaction in the form of a debt offering with a disclosed aggregate value of $10 billion USD. This is a primary debt issuance by the company in the healthcare industry. The transaction is sourced from SEC filings published on the SEC EDGAR system on August 4, 2026 and August 6, 2026. The specific SEC form type has not been identified. The current status of the transaction is pending regulatory approval. A substantial syndicate of financial advisors has been assembled to manage the offering, all serving in the capacity of joint book-running managers on behalf of the issuer. The lead book-running managers include Morgan Stanley, BofA Securities, J.P. Morgan, and Societe Generale, who are described as managing all notes issued in this offering. Additional joint book-running managers with specific tranche assignments include Deutsche Bank Securities managing the 2036 notes, Wells Fargo Securities managing the 2056 notes, Mizuho managing the 2031 notes, HSBC managing the 2033 notes, BNP Paribas managing the 2030 notes, Barclays managing the floating rate notes and 2028 notes, and Citigroup managing the 2038 notes and 2066 notes. This structuring reflects a multi-tranche offering with different maturity profiles, with individual managers assigned lead responsibility for specific note tranches while the primary managers coordinate the overall syndication. No legal advisors have been identified in the available source materials. The transaction structure involves multiple note tranches with distinct maturity dates ranging from 2028 through 2066, suggesting a laddered debt maturity profile. Specific terms regarding interest rates, coupons, pricing, or other consideration mechanics have not been disclosed in the available documentation. The offering includes both fixed-rate and floating-rate note components, as evidenced by Barclays' assignment to manage floating rate notes alongside specific tenor tranches. The expected closing date for this transaction has not been disclosed. The specific coupon rates, pricing spreads, and final terms for individual note tranches remain undisclosed. The aggregate $10 billion represents the total disclosed value but does not specify how much each individual tranche within the multi-tranche offering will comprise. No information regarding use of proceeds has been provided.

Accelerate Diagnostics, Inc., a healthcare company, is the target in an asset sale structured as a bankruptcy proceeding. This is a restructuring transaction with a disclosed value of $36,900,000 in U.S. dollars. The transaction was announced and is being tracked through SEC filings. The information regarding this transaction is sourced from an SEC filing published on May 8, 2025, through the SEC EDGAR system. While the specific form type is not identified in the available data, the filing confirms the announced status of the asset sale. No expected closing date or other timeline milestones have been disclosed. Accelerate Diagnostics retained three advisors to represent its interests in the transaction. Fried, Frank, Harris, Shriver & Jacobson LLP serves as legal counsel to the target. On the financial advisory side, Solic Capital is serving as financial advisor, while Perella Weinberg Partners L.P. is acting as restructuring investment banker. No advisors representing the acquirer or other parties to the transaction have been identified in the available source materials. No separate legal advisors beyond Fried, Frank, Harris, Shriver & Jacobson LLP have been disclosed. The legal representation appears to be consolidated under the single counsel identified for Accelerate Diagnostics. The transaction involves an asset sale of Accelerate Diagnostics' assets as part of a bankruptcy process, valued at $36,900,000. Beyond the aggregate disclosed value, no further detail regarding the consideration structure, whether cash or stock or mixed, has been provided. The specific identity of the acquirer or purchaser of the assets has not been disclosed in the available materials. Notable gaps in the public disclosure include the identity of the acquiring party, the expected closing date, the composition of the consideration (cash, stock, other instruments, or a combination thereof), any details regarding which specific assets are being sold, the terms of the bankruptcy sale process, and any additional conditions or milestones that may apply to the transaction. No information regarding potential financing or any debt arrangements related to the asset sale has been provided.

Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing precision therapies for immune-mediated diseases, and ACELYRIN, Inc. (Nasdaq: SLRN), a late-stage clinical biopharma company in immunology, announced a definitive all-stock merger agreement on February 6, 2025, disclosed in a Form 8-K that included a joint press release. Martin Babler, President, CEO and Chairman of Alumis, said the combination would give Alumis "the financial flexibility and runway to advance an expanded late-stage pipeline, now including lonigutamab, and build commercial capabilities." Bruce Cozadd, Chair of the ACELYRIN Board and a member of its Board Transaction Committee, said the deal was "the culmination of a thorough strategic review process by our Board and management team to determine the best and most value-maximizing path forward for ACELYRIN." Under the original merger agreement, each ACELYRIN share was to be exchanged for 0.4274 shares of Alumis common stock, which would have left Alumis stockholders owning approximately 55% and ACELYRIN stockholders approximately 45% of the combined company on a fully diluted basis. On April 20, 2025, the parties amended the merger agreement to increase the exchange ratio to 0.4814 Alumis shares per ACELYRIN share, after ACELYRIN disclosed that it had received a competing, unsolicited acquisition proposal from Tang Capital Partners (the "Tang Proposal") consisting of $3.00 per share in cash plus a contingent value right tied to 80% of net proceeds from any future out-license or disposition of ACELYRIN's development programs, according to the joint proxy statement/prospectus on Form S-4. Following the amendment, Alumis stockholders were expected to own approximately 52% and ACELYRIN stockholders approximately 48% of the combined company on a fully diluted basis. The S-4 states that the amended exchange ratio represented a premium of approximately 67% relative to the unaffected market-based exchange ratio of ACELYRIN common stock on February 6, 2025. No cash consideration, dollar-denominated enterprise value, or EV/EBITDA-type multiple has been disclosed for the transaction, consistent with its structure as a stock-for-stock exchange between two clinical-stage, pre-revenue biopharmaceutical companies. The companies disclosed a pro forma cash position of approximately $737 million as of December 31, 2024 (Alumis approximately $289 million and ACELYRIN approximately $448 million on a preliminary basis), which they said would provide runway into 2027. No cost synergy dollar figure or phase-in timeline was disclosed; the S-4/joint proxy statement cites only qualitative "cost synergies and operating efficiencies resulting from the elimination of redundant general and administrative costs" as a consideration for the ACELYRIN board, without quantifying the amount. Per the joint proxy statement/prospectus, the Alumis Special Committee retained Morgan Stanley & Co. LLC, which rendered a fairness opinion dated April 20, 2025 concluding the amended exchange ratio was fair, from a financial point of view, to Alumis. ACELYRIN retained Guggenheim Securities, LLC, which rendered a fairness opinion, dated February 6, 2025, as to the fairness of the original exchange ratio to ACELYRIN stockholders. The joint proxy/S-4 also discloses that ACELYRIN, assisted by Guggenheim Securities, contacted 27 strategic parties to assess a potential transaction, and that a separate process previously run by Aquilo Partners had contacted 32 parties regarding a partnership for ACELYRIN's izokibep program; neither process produced an actionable alternative to the Alumis transaction other than the Tang Proposal, which the ACELYRIN board ultimately did not pursue in lieu of the amended Alumis merger. Morgan Stanley & Co. LLC served as financial advisor to Alumis, and Cooley LLP served as its legal counsel. Guggenheim Securities, LLC served as financial advisor to ACELYRIN. ACELYRIN's legal representation included both Fenwick & West LLP, described in the S-4 as ACELYRIN's "recently engaged corporate counsel," and Paul Hastings LLP, identified in the S-4 as "legal counsel to ACELYRIN." Fenwick & West also delivered a tax opinion that the merger would more likely than not qualify as a tax-free "reorganization" under the Internal Revenue Code. The original merger agreement, filed as Exhibit 2.1 to the February 6, 2025 Form 8-K, provided for a $10.0 million termination fee payable by either party under specified circumstances, including termination to accept a superior proposal, and an outside date of July 7, 2025. Alumis stockholders approved the related share-issuance proposal at a special meeting held May 13, 2025, with approximately 88.98% of outstanding shares represented and 41,861,422 votes in favor versus 159,077 against, according to the Form 8-K reporting the vote (Item 5.07). The merger closed on May 21, 2025: ACELYRIN merged with Alumis' wholly owned merger subsidiary and became a wholly owned subsidiary of Alumis, with each ACELYRIN share converted into the right to receive 0.4814 shares of Alumis common stock, per the closing Form 8-K (Item 2.01). ACELYRIN stock options with an exercise price of $18.00 or less were converted into Alumis options at the exchange ratio; options with an exercise price above $18.00 were cancelled without consideration. Outstanding ACELYRIN RSUs and PSUs (with PSUs deemed earned at 100% of target) were converted into Alumis RSUs at the exchange ratio. In connection with the closing, Alumis' board was expanded and Lynn Tetrault was appointed as a new independent director; Henry Gosebruch, who had also been expected to join the board, did not do so after being named CEO of Galapagos. The combined company operates under the Alumis name, led by Alumis' pre-existing executive team, with its headquarters remaining in South San Francisco, California. As permitted under Item 9.01(a)(3) of Form 8-K, audited financial statements of the acquired business and pro forma financial information were to be filed by amendment within 71 days of the closing 8-K's required filing date; this research did not locate or confirm the filing of that amendment.

This transaction involves Alumis Inc. (ticker ALMS), a healthcare-sector company, as the acquirer, with ACELYRIN as the target, in an all-stock merger. The deal falls under the M&A product group, and its disclosed value is not stated in the source document. The facts are sourced from an 8-K filing with the SEC via EDGAR, published May 21, 2025. The deal's status is pending regulatory, indicating it had not yet closed as of that filing. Two financial advisors are disclosed, one per side, both designated lead. Guggenheim Securities, LLC served as financial advisor to ACELYRIN (the target), with the source sentence also noting that Fenwick & West LLP and Paul Hastings LLP served as ACELYRIN's legal counsel. On the acquirer side, Morgan Stanley & Co. LLC served as financial advisor to Alumis, with Cooley LLP serving as Alumis's legal counsel, per the corresponding source sentence. Legal advisors are disclosed for both sides. Cooley LLP served as legal counsel to the acquirer, Alumis. On the target side, both Paul Hastings LLP and Fenwick & West LLP served as legal counsel to ACELYRIN, reflecting that the target retained two separate law firms for the transaction. Beyond classifying the transaction as an all-stock merger, the facts block does not specify the exchange ratio, pro forma ownership split, or any other structural terms of the stock consideration. Several facts are not disclosed in this record. The transaction's dollar value is not stated. No expected closing date is given, and the facts block does not clarify the respective roles of ACELYRIN's two legal advisors, Fenwick & West LLP and Paul Hastings LLP, relative to one another.

Acutus Medical, Inc. announced on April 27, 2022 a comprehensive recapitalization combining a debt refinancing with Deerfield Management Company and a definitive agreement to sell the company's left-heart access portfolio to Medtronic. The left-heart access portfolio includes the AcQCross line of sheath-compatible septal crossing devices and the AcQGuide MINI, FLEX and VUE introducer and sheath products. This record is sourced from an Exhibit 99.1 press release furnished with Acutus Medical's Form 8-K filed April 27, 2022. At the time of announcement, the asset sale to Medtronic was a signed definitive agreement, not yet closed, and was conditioned on antitrust clearance and the simultaneous closing of Acutus's new debt facility. Perella Weinberg Partners served as sole financial advisor to Acutus on the transaction, per the release's statement that "Perella Weinberg Partners acted as financial advisor to Acutus, and Davis, Polk, & Wardwell served as legal advisors to the Company." No financial advisor to Medtronic is named in this release, and no lead designation applies since Perella Weinberg was Acutus's only disclosed advisor. On the legal side, Davis, Polk, & Wardwell advised Acutus, while Katten Muchin Rosenman LLP advised Deerfield (the refinancing lender) rather than Medtronic specifically. Under the terms, Medtronic was to make an upfront cash payment of $50 million to Acutus at initial closing, with additional contingent consideration payments tied to future development and regulatory milestones and future sales; separately, Deerfield committed to a new $35 million debt facility with a five-year maturity to replace Acutus's existing facility. Not disclosed in the sourced document is the aggregate potential value of the contingent milestone payments (only that they exist), the expected closing date of either the asset sale or the refinancing, or Medtronic's financial or legal advisors on the acquisition.

This transaction is a stock-for-stock merger in which Quanterix Corp (ticker QTRX), a healthcare sector company, is acquiring Akoya Biosciences, Inc. The deal is classified under the M&A product group, and the disclosed value is not stated in the source document. The facts in this briefing are sourced from an SEC EDGAR Form S-4 filed and published on March 28, 2025. The transaction's current status is pending regulatory review. Only one financial advisor is named in the facts block: Goldman Sachs & Co. LLC served as financial advisor to the acquirer, Quanterix, in a lead capacity. The source sentence references consent language for Goldman Sachs & Co. LLC's opinion letter under the caption The Merger, Opinion of Quanterix's Financial Advisor, confirming the firm's role was specifically to render a fairness opinion to Quanterix in connection with the merger. No legal advisors are identified in the facts block for either Akoya Biosciences or Quanterix. Beyond confirming the transaction is structured as a stock-for-stock merger, the facts block does not specify the exchange ratio, the treatment of outstanding equity awards or convertible securities, or any other structural terms of the merger agreement. Several material facts remain undisclosed. The transaction's dollar value is explicitly stated as not disclosed in the source document. No financial advisor is named for Akoya Biosciences, the target, and no legal advisors are named for either party. No expected closing date is given, and the specific stock exchange ratio is not disclosed.

ANI Pharmaceuticals, Inc., a Nasdaq-listed specialty pharmaceutical company, signed a definitive agreement to acquire Alimera Sciences, Inc., a global ophthalmology-focused pharmaceutical company, to expand ANI's rare disease business. The deal was structured as $5.50 per share in cash at closing plus a non-tradable contingent value right (CVR) worth up to $0.50 per share tied to 2026-2027 net revenue targets for Alimera's commercial products ILUVIEN and YUTIQ. The deal is sourced from a joint press release filed as an 8-K exhibit by ANI Pharmaceuticals on June 21, 2024, announcing the signed agreement, with a closing-confirmation 8-K filed later in September 2024 after the deal completed. Perella Weinberg Partners served as a financial advisor to Alimera, the target, in a non-lead capacity alongside lead advisor Centerview Partners LLC. The release states: "Centerview Partners LLC is acting as lead financial advisor to Alimera, with Perella Weinberg Partners also acting as a financial advisor to Alimera." On the acquirer side, Raymond James & Associates, Inc. is also named as a financial advisor to ANI, though the sentence structure ("is also acting as financial advisor") suggests an additional advisor to ANI's primary deal team not fully captured in the excerpt. Hughes Hubbard & Reed LLP served as legal advisor to ANI, and DLA Piper served as legal advisor to Alimera. The transaction valued Alimera at approximately $381 million in upfront consideration, consistent with the $5.50-per-share cash price before the CVR. The deal was expected to close late in the third quarter of 2024, subject to customary closing conditions including regulatory approvals and Alimera shareholder approval; it subsequently closed, per the separately filed closing 8-K dated September 16, 2024. Not disclosed in the reviewed excerpt: the specific net revenue targets that would trigger CVR payment, the identity and role of ANI's lead financial advisor (if distinct from Raymond James), and the maximum aggregate CVR payout value across all Alimera shares.

Tarsus Pharmaceuticals, Inc., a publicly traded healthcare company trading under the ticker TARS, is acquiring Alkeus in an all-stock or cash transaction valued at $450 million. This is a mergers and acquisitions deal within the healthcare sector. The transaction is currently pending regulatory approval. The deal information has been sourced from an SEC filing published on the SEC EDGAR database on August 6, 2026. The specific form type is not identified in the available documentation. Given the pending regulatory status, the transaction has not yet closed and remains subject to customary conditions and regulatory clearance. Barclays is serving as the exclusive financial advisor to Tarsus, the acquirer, in a lead capacity on this transaction. On the target side, Jefferies is acting as the exclusive financial advisor to Alkeus, also in a lead advisory role. Both firms are providing comprehensive financial advisory services to their respective clients throughout the deal process. Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP is providing legal counsel to Tarsus in connection with the acquisition. Latham & Watkins LLP is serving as legal counsel to Alkeus, the target company. Both firms are handling all legal matters related to the transaction for their respective clients. The transaction is valued at $450 million, though the specific mix of consideration, whether structured as cash, stock, or a combination thereof, has not been disclosed. The deal structure remains undisclosed beyond the headline valuation figure. No information has been provided regarding the relative weighting between cash and equity consideration, any earnout provisions, closing conditions beyond regulatory approval, timing for regulatory review, or an expected closing date. The target company Alkeus' sector classification and operational details have not been specified. Additionally, the specific regulatory agencies with jurisdiction over this transaction and their anticipated approval timelines have not been disclosed.

Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) announced on August 6, 2026 that it has entered into a definitive agreement to acquire Alkeus Pharmaceuticals, Inc., a privately held, retinal disease-focused biotechnology company developing gildeuretinol (ALK-001), an investigational once-daily oral therapy for Stargardt disease, a rare inherited retinal disease with no FDA-approved treatment. Tarsus said the acquisition is intended to expand its presence in retina therapeutics and complement its existing eye care pipeline, including the earlier acquisition of iRenix Medical. This record is sourced from Tarsus's own press release, furnished as an exhibit to an 8-K filed with the SEC on August 6, 2026. The release states the transaction has been approved by the boards of directors of both companies and by Alkeus's stockholders, and that closing is not contingent on any financing condition. Barclays is acting as exclusive financial advisor to Tarsus on the acquirer side. Jefferies is acting as exclusive financial advisor to Alkeus on the target side. Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP is acting as legal counsel to Tarsus. Latham & Watkins LLP is acting as legal counsel to Alkeus. The upfront consideration is approximately $450 million, consisting of $270 million in cash and $180 million in Tarsus common stock priced at $61.38 per share at closing, roughly a 60/40 cash-to-stock split. Alkeus stockholders are also eligible for up to $350 million in milestone payments tied to regulatory approval and first commercial sale, plus low single digit tiered descending royalties on gildeuretinol net sales. The transaction is expected to close in 2026, subject to expiration or termination of the Hart-Scott-Rodino waiting period and other customary closing conditions. Not disclosed in this filing: the specific HSR filing or antitrust review timeline beyond the standard waiting period reference, any termination fee, Alkeus's historical financials, and the precise royalty percentage range (described only as "low single digit").

Anebulo Pharmaceuticals, Inc., a Delaware corporation in the healthcare sector trading on the Nasdaq Capital Market under ticker ANEB, commenced an issuer self-tender offer on December 22, 2025 to purchase up to 300,000 shares of its common stock at a fixed price of $3.50 per share, for an aggregate purchase price of up to approximately $1,050,000 in cash. The Offer was structured as part of a going-private transaction under Rule 13e-3 and was disclosed in a combined Schedule TO / Schedule 13E-3 (Schedule TO-I) filed with the SEC, together with an accompanying Form 8-K (Items 8.01 and 9.01) and press release. According to the Offer to Purchase, the Board established a Strategic and Review Committee (the "Special Committee"), composed of independent directors, in February 2025 to evaluate strategic alternatives including a potential going-private transaction. The Special Committee and the Board determined that "the costs of being an SEC reporting company outweigh the benefits" and that it was no longer in the best interests of stockholders to remain an SEC reporting company. The stated primary purpose of the Offer was to reduce the number of record holders of common stock below 300, the threshold at or above which SEC public reporting is required, allowing the Company to deregister under the Exchange Act, suspend periodic reporting, and delist from Nasdaq. Anebulo estimated it would save approximately $1.3 million per year in costs (auditor and legal fees, Nasdaq fees, printing and mailing, internal compliance, transfer agent costs, and higher director/officer insurance premiums and board compensation associated with being public) if it became a private company. The Offer to Purchase discloses that the Board determined to offer $3.50 per share "after considering our current financial condition and the limited opportunities for liquidity available for our stockholders." The $3.50 offer price represented a premium to the $2.17 Nasdaq closing price on December 19, 2025, the last full trading day before commencement of the Offer, and to the $1.83 closing price on July 22, 2025, the last trading day before Anebulo announced its intention to go private. The transaction's background section discloses that the Special Committee originally pursued a reverse stock split (with a split ratio range of not less than 1-for-2,500 and not greater than 1-for-7,500 Shares and a $3.50 cash payment for fractional shares) before ultimately pursuing the tender offer structure instead. Houlihan Capital, LLC was retained by the Special Committee in June 2025 to render a fairness opinion; Houlihan Capital delivered a "bring down" fairness opinion dated December 17, 2025 concluding that the cash tender offer at $3.50 per share was fair, from a financial point of view, to the Company's unaffiliated stockholders. The Offer was not subject to a financing condition or a minimum tender condition, and Anebulo stated it would pay for the Shares, including related fees and expenses, from cash on hand. As of December 19, 2025, the Company had 41,084,731 shares outstanding; a fully subscribed Offer would represent approximately 0.7% of shares outstanding. The Offer to Purchase discloses that Anebulo's directors and executive officers (nine persons, collectively beneficially owning approximately 80.0% of outstanding shares before the Offer) informed the Company they would not tender any shares, which the filing states would raise their collective beneficial ownership to approximately 80.5% if the Offer were fully subscribed. The Offer was originally scheduled to expire on January 26, 2026 and was amended twice (January 8, 2026 and January 27, 2026) before a Final Amendment on Schedule TO-I/A filed January 29, 2026 reported the results: the Offer expired as scheduled on January 26, 2026, was oversubscribed with 4,907,881 shares validly tendered, and Anebulo accepted 300,000 shares for payment (including 134,306 "odd lots" accepted in full, with other tenders prorated at a factor of approximately 3.47392%), for an aggregate cost of approximately $1.05 million excluding fees and expenses, representing approximately 0.73% of shares outstanding as of the January 26, 2026 expiration. Payment was wired to the depositary on January 29, 2026. Following completion of the tender offer, Anebulo's Board approved voluntary delisting from Nasdaq and deregistration with the SEC, as disclosed in a Form 8-K (Items 3.01 and 8.01) filed February 6, 2026 reporting Board action taken February 5, 2026. The Company filed a Form 25 to delist from Nasdaq (filed February 17, 2026 per EDGAR records) and subsequently filed a Form 15-12G on March 2, 2026 certifying fewer than 300 holders of record and terminating its registration under the Exchange Act, confirming the going-private transaction was completed and Anebulo's SEC reporting obligations were suspended. Blank Rome LLP, with attorneys Leslie Marlow and Melissa Murawsky, served as the Company's outside legal counsel throughout the going-private process, as identified on the Schedule TO cover page and referenced throughout the Offer to Purchase's background section. No financial advisor fairness-opinion fee or underwriting/dealer-manager fee amount was disclosed in the sections reviewed. Broadridge Corporate Issuer Solutions, LLC acted as depositary and information agent for the Offer.

This record concerns Anebulo Pharmaceuticals, Inc. (ticker ANEB), a healthcare-sector company, acting as both target and issuer in a going-private transaction structured as a reverse stock split. The deal falls under the M&A product group, and its disclosed value is not stated in the source document. The facts are sourced from an SC 13E3 filing with the SEC via EDGAR, published July 23, 2025. The deal's status is pending regulatory, indicating the going-private process had not yet concluded as of that filing. Only one financial advisor is disclosed: Houlihan Capital, LLC, which served as financial advisor and fairness opinion provider to the company and is designated lead. The source sentence notes that the fairness opinion of Houlihan Capital, LLC, dated July 15, 2025, was made available for inspection and copying at the company's principal executive offices, indicating the opinion addressed the fairness of the reverse stock split transaction to affected stockholders. The only legal advisor disclosed is Blank Rome LLP, serving as counsel to the company. The source sentence is a notice/copy line from the filing listing attorneys Leslie Marlow, Esq. and Melissa Palat Murawsky, Esq. of Blank Rome LLP as recipients of filing copies, indicating the firm's role as counsel in the matter. Beyond classifying the transaction as a going-private reverse stock split, the facts block does not specify the split ratio, the cash-out price for fractional shares, or other mechanical terms of the reverse split. Several facts are not disclosed in this record. The transaction's dollar value is not stated. No expected closing date is given, and the facts block does not specify the reverse stock split ratio or the treatment of stockholders who would be cashed out as a result of the split.

Aptose Biosciences Inc., a clinical-stage biotechnology company trading on the Toronto Stock Exchange, agreed to be taken private by Hanmi Pharmaceutical Co., Ltd., a Korean pharmaceutical company, through Hanmi's wholly owned subsidiary HS North America Ltd. The companies entered into a definitive arrangement agreement on November 18, 2025, which was later amended and restated on February 23, 2026, primarily to move the shareholder vote date from January 16, 2026 to March 31, 2026. The transaction closed on June 30, 2026, after the Court of King's Bench of Alberta approved the arrangement on March 31, 2026. Under the terms of the arrangement, each Aptose common share not already owned by Hanmi was converted into the right to receive C$2.41 in cash, representing a 28 percent premium to Aptose's 30-day volume-weighted average price of C$1.88 on the TSX as of the November 2025 announcement. Hanmi already owned 508,710 common shares, or 19.93 percent of Aptose's 2,552,429 shares outstanding, prior to closing, stemming from its position as Aptose's existing lender. The aggregate cash consideration paid for the 2,043,719 minority shares was approximately US$3,466,470 (C$4,925,362.79), excluding transaction fees and expenses, implying a total equity value for all outstanding shares of roughly C$6.15 million. No enterprise value, EV/EBITDA, or P/E multiple was disclosed, consistent with Aptose being a pre-revenue clinical-stage company; the merger proxy states Aptose had more liabilities than assets and a shareholder's deficit, and the Transaction Committee therefore did not consider book value or going-concern value material to the fairness analysis. The consideration was all cash with no financing condition. Locust Walk Securities, LLC, financial advisor to Aptose's Special Committee (referred to as the Transaction Committee), delivered a formal valuation under Canadian multilateral instrument MI 61-101 concluding a fair market value range of C$1.00 to C$5.08 per share, and a fairness opinion concluding the C$2.41 cash consideration was fair, from a financial point of view, to the minority shareholders. The Transaction Committee and Board, after a targeted market check to solicit alternative acquirers or licensees for Aptose's lead drug candidate tuspetinib that produced no superior proposals, unanimously recommended the arrangement, citing the cash premium, certainty of value, and the company's limited alternatives given continuing dependence on Hanmi-provided financing and the risk of insolvency absent the deal. The arrangement agreement included customary non-solicitation covenants with a right for Hanmi to match competing proposals, and an expense fee of C$300,000 payable by Aptose to Hanmi if the agreement were terminated in specified circumstances, including a change in the board's recommendation or acceptance of a superior proposal. There was no reverse break fee payable by Hanmi. Completion required approval by at least two-thirds of votes cast by Aptose shareholders at a special meeting, plus Alberta court approval, both of which were obtained. Concurrently with signing, Hanmi Purchaser entered into voting support agreements with all of Aptose's directors and officers, who agreed to vote their shares in favor of the transaction. Following the closing, Aptose became a wholly owned subsidiary of the Hanmi Purchasers, all of Aptose's directors resigned, the common shares were delisted from the TSX on or about July 3, 2026, and Aptose filed a Form 15-12G to deregister from SEC reporting obligations. McCarthy Tetrault LLP acted as legal counsel to Aptose and its Transaction Committee throughout the negotiation, and Stikeman Elliott LLP acted as legal counsel to Hanmi as Parent. No synergy estimates, pro forma ownership splits, or post-closing integration targets were disclosed in the filings reviewed, consistent with this being a 100 percent cash squeeze-out of a small, financially distressed clinical-stage company by its controlling lender rather than a stock-for-stock strategic combination.

Aptose Biosciences Inc., a healthcare sector company, is the target of a going-private transaction. The acquiring entity is Hanmi Purchaser. This is a mergers and acquisitions transaction classified as a going-private deal. The disclosed value of the transaction is not stated in the source document. The information regarding this transaction is sourced from an SEC EDGAR filing published on November 19, 2025. The specific form type is not identified in the source materials. The deal is currently in pending regulatory status. On the acquirer side, Stikeman Elliott LLP is serving as independent legal advisor to Hanmi Purchaser. On the target side, Locust Walk Securities LLC is acting as financial advisor and independent valuator to both the Special Committee and the Company. McCarthy Tétreault LLP is serving as independent legal advisor to the Special Committee and the Company. Both Locust Walk Securities and McCarthy Tétreault are positioned as lead advisors on their respective roles. Stikeman Elliott LLP represents Hanmi Purchaser in a legal advisory capacity. McCarthy Tétreault LLP represents the target company's Special Committee and the Company itself in a legal advisory capacity. The specific structure, consideration mix, and terms of the transaction are not disclosed in the available source materials. The following material details remain undisclosed or unknown: the transaction value or purchase price; the specific consideration structure (whether cash, stock, or a combination thereof); the anticipated closing date; the detailed transaction structure and any conditions precedent; the form type of the SEC filing containing this information; and any other material deal terms. Additionally, the current stage of regulatory review and whether any regulatory approvals remain pending is not specified beyond the pending regulatory status notation.

Artelo Biosciences, Inc., a healthcare sector company trading under ticker ARTL on the Nasdaq Capital Market, entered into an At-The-Market Offering Agreement on July 18, 2025 with R.F. Lafferty & Co., Inc. as exclusive sales agent, under which the company may sell up to an aggregate of $6,500,000 of shares of its common stock, par value $0.001 per share, from time to time at prevailing market prices. The agreement and the related prospectus supplement (Form 424B5) were both filed with the SEC on July 18, 2025, the same day the 8-K announcing the agreement was filed. Under the terms of the sales agreement, Lafferty is entitled to a commission of 2.0% of the gross sales price per share sold, and is deemed an underwriter within the meaning of the Securities Act in connection with those sales, with its compensation treated as underwriting commissions or discounts. Lafferty is not required to sell any specific number or dollar amount of shares and acts on a best-efforts basis. The prospectus supplement notes that, as of the pricing date, the last reported sale price of Artelo common stock on Nasdaq was $15.67 per share (July 17, 2025 close), which was used as an assumed offering price solely for illustrative purposes in the filing's dilution and share-count disclosures; the filing does not state that any shares were actually sold at that price. The prospectus supplement's illustrative dilution table shows that, as of March 31, 2025, Artelo's historical net tangible book value was approximately $(1.4) million, or $(2.44) per share, based on 567,582 shares then outstanding. Assuming the full $6.5 million were sold at $15.67 per share (yielding approximately $6.2 million in estimated net proceeds after commissions and offering expenses), the filing illustrates a pro forma as-adjusted net tangible book value of $4.87 per share, an increase of $7.31 per share for existing stockholders, and dilution of $10.80 per share to new investors at that assumed price. These figures are explicitly labeled illustrative, and the filing states actual results would vary with the real offering price and timing of sales. On use of proceeds, Artelo stated it intends to use net proceeds from the ATM program to advance its product candidates through preclinical and clinical development, including manufacturing, research and technical development, clinical studies, and capital expenditures, as well as for working capital and general corporate purposes. The company also disclosed it may use proceeds for investments in complementary products or technologies, though it had no present commitments or agreements for any such investments as of the filing date. No debt repayment or acquisition-specific use of proceeds was disclosed. R.F. Lafferty & Co., Inc. serves as the sole sales agent to the issuer under the ATM program. Fennemore Craig, P.C. of Reno, Nevada, serves as legal counsel to Artelo and passed on the validity of the shares offered. Ellenoff Grossman & Schole LLP of New York, New York, is disclosed in the prospectus supplement as counsel to Lafferty in connection with the offering. Subsequent SEC filings show modest actual utilization of this ATM program. According to Artelo's Form 10-Q for the quarter ended September 30, 2025, and its Form 10-K for the year ended December 31, 2025, a total of 50,858 shares of common stock were sold under the Sales Agreement during the third quarter of 2025, generating net proceeds of $442,000, all of which occurred during that single quarter (the 10-K's full-year figure for 2025 matches the Q3 figure, indicating no further sales under this particular agreement in the fourth quarter). This represents roughly 6.8% of the $6.5 million maximum authorized under the program. No prospectus supplement, pricing 8-K, or other filing specifies the actual per-share prices at which the 50,858 shares were sold, the gross (as opposed to net) proceeds from those sales, or the specific dates within the third quarter when the sales occurred. There is no free-writing prospectus or formal underwriting agreement associated with this ATM program, consistent with its structure as an agency-basis at-the-market offering rather than a firm-commitment underwritten deal. Artelo separately entered into an underwritten offering with R.F. Lafferty as sole book-running manager in September 2025, but that was a distinct transaction executed under a separate underwriting agreement and is not part of this $6.5 million ATM program. The ATM program itself has not been reported as formally terminated or fully utilized in any filing reviewed.

This deal is an asset divestiture structured as a cash acquisition, classified as an M&A transaction in the healthcare sector, involving the Baqsimi product (divested by Lilly) and Amphastar Pharmaceuticals, Inc. (ticker AMPH) as acquirer. The disclosed value of the transaction is $625,000,000. The transaction is sourced from an 8-K filing with the SEC, filed via SEC EDGAR and published on April 24, 2023. The deal's current status is pending regulatory approval. On the financial advisory side, J.P. Morgan Securities LLC acted as financial advisor to Lilly, the target/divesting party, in a lead capacity. Jefferies LLC acted as financial advisor to Amphastar, the acquirer, also in a lead capacity, with each advisor paired with its respective legal counsel in the source material. On the legal side, two firms represented Lilly (the target/divesting party): Kirkland & Ellis LLP and Covington & Burling LLP, both named as legal counsel in the same source sentence as J.P. Morgan's role. Wilson, Sonsini, Goodrich & Rosati, P.C. represented Amphastar, the acquirer, as legal counsel. Beyond the cash consideration for this asset divestiture, with a disclosed deal value of $625,000,000, no further detail on specific terms of the asset transfer beyond it being a product/asset acquisition is provided in the facts block. Several items are not disclosed in the available record. No further structural detail beyond the asset divestiture and cash acquisition classification is given, and no expected closing date or further timeline detail beyond the April 2023 filing date and pending-regulatory status is provided.

BillionToOne, Inc., a healthcare company trading on the Nasdaq under the ticker BLLN, completed its initial public offering on November 7, 2025. The offering consisted of an aggregate of 5,233,765 shares of Class A common stock, which included the full exercise of the underwriters' option to purchase an additional 682,665 shares, at a public offering price of $60.00 per share. The base offering, before the overallotment option, was 4,551,100 shares, representing $273,066,000 in gross proceeds as stated on the prospectus cover page. With the overallotment exercised in full, aggregate gross proceeds were approximately $314.0 million, before deducting underwriting discounts, commissions, and offering expenses. The prospectus, dated November 5, 2025 and filed as a Form 424B4 on November 6, 2025, disclosed estimated net proceeds to the company of approximately $248.4 million based on the base offering, or approximately $286.4 million assuming full exercise of the overallotment option, after underwriting discounts and commissions and estimated offering expenses. The underwriting discount was $4.20 per share, totaling $19,114,620 on the base offering and $21,981,813 assuming full exercise of the option, consistent with the actual outcome since the option was exercised in full. J.P. Morgan Securities LLC, Piper Sandler & Co., Jefferies LLC, and William Blair & Company, L.L.C. acted as joint book-running managers and representatives of the underwriters. The prospectus's underwriting table disclosed specific share allocations among the syndicate: J.P. Morgan Securities LLC (1,592,885 shares), Piper Sandler & Co. (910,220 shares), Jefferies LLC (682,665 shares), William Blair & Company, L.L.C. (523,377 shares), Stifel, Nicolaus & Company, Incorporated (318,577 shares), Wells Fargo Securities, LLC (295,822 shares), and BTIG, LLC (227,554 shares), totaling 4,551,100 shares. The company also reserved up to 5 percent of the shares offered for sale at the IPO price to officers, directors, employees, and certain individuals identified by management through a directed share program. The company stated that it intends to use the net proceeds from the offering, together with existing cash and cash equivalents, for working capital and other general corporate purposes, including funding growth, research and development initiatives, technology development, and operating expenses. The prospectus specifically disclosed that the company does not currently have specific planned uses for the proceeds and may use a portion to acquire or invest in complementary products, technologies, or businesses, though it had no agreements or commitments for any such transactions as of the prospectus date. On a dilution basis, the prospectus disclosed that the company's historical net tangible book value deficit as of June 30, 2025 was $(22.46) per share, and its pro forma net tangible book value (reflecting preferred stock conversion and related reclassifications occurring immediately prior to the offering) was $4.25 per share. After giving effect to the sale of 4,551,100 shares at $60.00 per share, pro forma as adjusted net tangible book value was $9.43 per share, representing an immediate increase of $5.18 per share to existing stockholders and immediate dilution of $50.57 per share to new investors in the base offering. Assuming full exercise of the overallotment option, pro forma as adjusted net tangible book value would increase to $10.12 per share, with dilution to new investors of $49.88 per share. As this was the company's initial public offering, there was no prior public trading price against which to measure a premium or discount at pricing; the $60.00 per share price was set through the IPO bookbuilding process rather than relative to an existing market price. On the legal side, the prospectus disclosed that Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP of San Francisco passed on the validity of the shares being offered on behalf of BillionToOne, while Cooley LLP of San Francisco represented the underwriters in connection with the offering. On the closing timeline, BillionToOne filed its registration statement on Form S-1 on October 7, 2025, amended it on October 17, 2025, registered its Class A common stock for listing on Nasdaq via Form 8-A12B on November 3, 2025, priced the offering with the final prospectus dated November 5, 2025 (filed as a 424B4 on November 6, 2025), and completed the IPO closing on November 7, 2025, as confirmed in a Form 8-K filed November 10, 2025. In that closing 8-K, the company also reported that it filed its amended and restated certificate of incorporation and that its amended and restated bylaws became effective in connection with the IPO closing. Based on this closing 8-K, the offering has fully closed; it is not pending regulatory review as previously indicated.

BioCorRx Inc. (ticker BICX), a Nevada-incorporated healthcare company based in Anaheim, California, entered into a stock exchange agreement on March 26, 2026 with three related-party shareholders of its majority-owned subsidiary, BioCorRx Pharmaceuticals, Inc.: Lourdes Felix (BioCorRx's Chief Executive Officer and a director), Louis C. Lucido (BioCorRx's President and a director), and Kent Emry (a director). Under the agreement, the three shareholders transferred to BioCorRx Inc. an aggregate of 1,215 shares of BioCorRx Pharmaceuticals common stock, representing approximately 12.15% of the subsidiary's outstanding common stock, in exchange for an aggregate of 2,263,371 newly issued shares of BioCorRx Inc. common stock, par value $0.001 per share. The exchange, referred to in the filings as "the Exchange," closed on March 27, 2026, the day after signing. The Exchange was undertaken pursuant to a Plan of Reorganization that BioCorRx Inc.'s board adopted on February 25, 2026, under which the company intends to acquire full control of BioCorRx Pharmaceuticals within the meaning of Section 368(c) of the Internal Revenue Code. The Exchange itself was structured to qualify as a tax-free reorganization under Section 368(a)(1)(B) of the Code. The company's common stock issued to the shareholders constituted the sole consideration; no cash or other property was paid or transferred. Because the recipients are officers and directors of BioCorRx Inc., the board approved the Exchange under the company's related-party transaction policy, and the agreement grants the shareholders certain registration rights for the shares received, subject to limitations. No purchase price, enterprise value, or per-share exchange price is disclosed in the filings; the agreement fixed the consideration as a specific share count (2,263,371 shares) rather than a formula tied to a valuation or exchange ratio. BioCorRx Inc.'s first-quarter 2026 Form 10-Q quantifies the accounting impact: the acquisition of the noncontrolling interest was recorded through equity, increasing the noncontrolling interest balance by $158,835 with an offsetting $161,098 adjustment within additional paid-in capital, moving the reported noncontrolling interest deficit from $(303,429) at December 31, 2025 to $(173,259) at March 31, 2026 (a change that also reflects a $28,665 net loss allocation to the noncontrolling interest during the quarter). Because BioCorRx Inc. already controlled and consolidated BioCorRx Pharmaceuticals before the Exchange, the transaction was accounted for as an equity transaction between owners rather than a new business combination; no goodwill or purchase-price allocation is disclosed in connection with it. The 10-Q states that BioCorRx Inc.'s ownership interest in BioCorRx Pharmaceuticals (and its share of the subsidiary's earnings) increased from 75.8% before March 26, 2026 to 88.15% afterward, with the noncontrolling interest's share of earnings correspondingly reduced from 24.2% to 12.85%. BioCorRx Pharmaceuticals is the operating subsidiary that in 2025 acquired certain assets, including the FDA-approved opioid-withdrawal medication Lucemyra, from USWM, LLC (d/b/a US WorldMeds) under a separate asset purchase agreement; that prior acquisition is unrelated to this stock exchange but provides context on the subsidiary being consolidated. No financial advisor or legal advisor is identified in any filing related to this transaction; given its nature as an internal, related-party exchange of minority shares for parent stock under a board-adopted reorganization plan, outside advisors may not have been retained, or their involvement was not disclosed. The Exchange has already closed. BioCorRx Inc.'s Form 8-K filed April 2, 2026 states explicitly that "The Exchange closed on March 27, 2026," and the company's Form 10-Q for the quarter ended March 31, 2026 confirms the share issuance and resulting ownership-percentage shift occurred during that quarter. No pending regulatory approval, shareholder vote, or other closing condition is referenced in any filing; the transaction was a private issuance exempt from registration under Section 4(a)(2) of the Securities Act, based on the restricted, non-public nature of the offer, the direct negotiation between the company and the three accredited-investor shareholders, and the absence of any general solicitation.

This deal is a cash and stock acquisition classified as an M&A transaction in the healthcare sector, involving BioLife Solutions Inc (ticker BLFS) as target and Repligen Corp (ticker RGEN) as acquirer. The disclosed value of the transaction is not stated in the source document. The transaction is sourced from an 8-K filing with the SEC, filed via SEC EDGAR and published on October 6, 2026. The deal's current status is pending regulatory approval. On the financial advisory side, Perella Weinberg Partners LP and Goldman Sachs & Co. LLC served as financial advisors to Repligen, the acquirer, with no lead designation specified for either firm. Centerview Partners, LLC served as financial advisor to BioLife, the target, also without a specified lead designation. On the legal side, Goodwin Procter LLP served as legal counsel to Repligen, the acquirer, while K&L Gates LLP served as legal counsel to BioLife, the target. Beyond the cash and stock consideration mix noted in the deal subtype, no further detail on the specific split between cash and stock components is provided in the facts block. Several items are not disclosed in the available record. The overall transaction value is not stated in the source document, no lead designation is specified for any of the financial advisors named, the precise cash-versus-stock consideration split is not broken out beyond the general subtype classification, and no expected closing date or further timeline detail beyond the October 2026 filing date and pending-regulatory status is given.

Boundless Bio, Inc. (Nasdaq: BOLD) and Serapha Bio, Inc., a privately held biotechnology company developing an investigational in vivo base editing therapy for Alpha-1 Antitrypsin Deficiency, announced on June 23, 2026 that they have entered into a definitive merger agreement to combine in an all-stock transaction. The combined company is expected to operate as Serapha Bio, Inc. and trade on Nasdaq under the ticker "AATD," advancing Serapha's lead program SERP-01, which targets the SERPINA1 E342K mutation underlying severe AATD. Boundless Bio's CEO said its oncology program BBI-940, aimed at extrachromosomal DNA biology, did not produce clinical data supporting continued advancement, prompting the strategic combination. This record is sourced from Boundless Bio's own 8-K press release (Exhibit 99.1), furnished to the SEC on June 23, 2026. The release states the transaction has received unanimous board approval from both companies and is paired with a concurrent private placement financing. Lucid Capital Markets is serving as exclusive financial advisor to Boundless Bio. Wedbush Securities Inc. is serving as exclusive financial advisor to Serapha. Latham & Watkins LLP is serving as legal counsel to Boundless Bio. Gibson, Dunn & Crutcher LLP and Goodwin Procter LLP are serving as legal counsel to Serapha. Under the merger agreement, pre-merger Boundless Bio stockholders are expected to own approximately 3.7% of the combined company and pre-merger Serapha stockholders approximately 96.3%. Serapha has secured commitments for an oversubscribed private placement of approximately $230 million co-led by RA Capital Management and RTW Investments, with participation from Janus Henderson Investors, Decheng Capital, Vivo Capital, Casdin Capital, LifeSci Venture Partners, Logos Capital, Balyasny Asset Management, and Eventide Asset Management; approximately $138 million of that total was already funded in a prior Series A round, with the remaining $92 million expected to close alongside the merger. Boundless Bio expects to declare a cash dividend of approximately $44 to $48 million to its pre-merger stockholders prior to closing. The deal is expected to close in the fourth quarter of 2026, subject to stockholder approval at both companies, Nasdaq listing approval, S-4 effectiveness, and expiration of the Hart-Scott-Rodino waiting period if applicable. Not disclosed in this filing: the exact final ownership split subject to net cash adjustment, any termination fee, and Serapha's financial terms with YolTech Therapeutics beyond the disclosed milestone and royalty structure for its separately licensed SERP-01 asset.

This transaction involves CareMax, Inc., a healthcare sector company, and is structured as a Chapter 11 asset sale under a prearranged plan, specifically involving CareMax's management services organization (MSO) business being sold to Revere Medical, an affiliate referred to in parts of the record as ClareMedica. The deal falls under the restructuring product group, and the disclosed value is not stated in the source document. This summary draws on two SEC EDGAR Form 8-K filings, one published on November 18, 2024, and a second published on November 25, 2024, reflecting the staged disclosure typical of a Chapter 11 process. The transaction's current status is pending regulatory review. The advisory roster reflects the multi-constituency nature of a bankruptcy sale process. Piper Sandler & Co. is serving as investment banker to CareMax, the debtor, in a lead role, a mandate referenced twice in the source material. Alvarez & Marsal North America, LLC is also serving as financial advisor to CareMax, likewise in a lead capacity, again referenced in two separate source sentences. On the creditor side, Guggenheim Securities, LLC is serving as financial advisor and investment banker to the current secured lenders, in a lead role. On the buyer side, Raymond James & Associates, Inc. is serving as investment banker to ClareMedica and its affiliates, the acquiring entity associated with Revere Medical, and Ernst & Young LLP is serving as financial advisor to ClareMedica, both in lead roles. Legal counsel also reflects this multi-party structure. Sidley Austin LLP is serving as legal counsel to CareMax, referenced twice in the source material. Ropes & Gray LLP is serving as legal counsel to the current secured lenders, alongside Guggenheim Securities' financial advisory role for that same creditor group. McGuireWoods LLP is serving as legal counsel to ClareMedica, alongside Ernst & Young LLP's financial advisory role for that buyer entity. The facts block identifies this as a Chapter 11 asset sale conducted under a prearranged plan, meaning the sale terms were negotiated with key creditor constituencies before the bankruptcy filing, specifically involving the sale of CareMax's MSO business to Revere Medical and ClareMedica, but it does not disclose the specific purchase price, the treatment of other creditor classes, or the timeline for plan confirmation. Several material facts are not disclosed. The transaction's dollar value is explicitly stated as not disclosed in the source document. No sector classification is given beyond CareMax's own healthcare designation. No expected plan confirmation or closing date is given, and no detail on the treatment of unsecured creditors or equity holders under the prearranged plan is provided.

This deal involves a strategic review and potential sale process, classified as an M&A transaction in the healthcare sector, involving DarioHealth Corp. (ticker DRIO) as the target/subject company. The disclosed value of the transaction is not stated in the source document, consistent with the fact that this is a review process rather than a signed transaction with agreed terms. The transaction is sourced from an 8-K filing with the SEC, filed via SEC EDGAR and published on September 25, 2025. The deal's current status is pending regulatory approval. On the financial advisory side, Perella Weinberg Partners is identified as financial advisor to DarioHealth, in a lead capacity. The source material notes that in connection with this review, DarioHealth's Board of Directors established a Special Committee of independent directors and engaged Perella Weinberg Partners as financial advisor to assist with that process. No legal advisors were extracted for this deal in the facts block, so it is not possible to state which law firms, if any, are advising the company or any potential counterparties in this process. Beyond the engagement of a financial advisor to support a strategic review and potential sale process, no further detail on specific transaction terms, potential acquirers, or structural considerations is provided in the facts block, which is consistent with this being characterized as a review process rather than a definitive agreement. Several material facts are not disclosed in the available record. No transaction value is stated, since no definitive transaction has been announced as of the facts given. No legal advisors are identified, no potential acquirer or counterparty is named, and no expected timeline or outcome for the strategic review is given beyond the pending-regulatory status noted in the September 2025 filing.

This transaction is a take-private cash acquisition in which Patient Square Capital is acquiring Eargo, Inc., a healthcare sector company. The deal falls under the M&A product group, and the disclosed value is not stated in the source document. This summary is sourced from an SEC EDGAR Form 8-K filed and published on February 16, 2024. On the financial advisory side, only one advisor is named: Perella Weinberg Partners LP acted as financial advisor to the special committee of Eargo's board, the target side, though no lead or non-lead designation is given for this role. No financial advisor is named for Patient Square Capital, the acquirer. Legal counsel, by contrast, is more fully documented across three firms. Ropes & Gray LLP acted as legal counsel to Patient Square, the acquirer. On the target side, two firms are named: Davis Polk & Wardwell LLP acted as legal counsel to the special committee, alongside Perella Weinberg's financial advisory role for that same committee, while Freshfields Bruckhaus Deringer LLP acted as legal counsel to the company, Eargo itself, as distinct from the special committee. The facts block confirms this is structured as a take-private cash acquisition, but provides no further detail on the per-share price, financing sources for Patient Square Capital, or any other structural terms of the transaction. Several material facts are not disclosed. The transaction's dollar value is explicitly stated as not disclosed in the source document. No financial advisor is named for the acquirer, Patient Square Capital. No expected closing date is given, and no detail on the purchase price per share is provided beyond the general cash acquisition characterization.

Envoy Medical, Inc., a healthcare company trading on Nasdaq under the ticker COCH, entered into an at-the-market offering agreement to sell up to $15,000,000 of Class A Common Stock. The agreement with the sales agent was dated January 17, 2025, and the transaction was announced the same day the related prospectus supplement was dated, with both the current report on Form 8-K and the Form 424(b)(5) prospectus supplement filed with the SEC on January 21, 2025. Roth Capital Partners, LLC serves as the sole sales agent for the offering. Under the ATM agreement, Envoy Medical will pay Roth Capital Partners a fixed commission of up to 3.0% of the gross sales price per share sold through the facility. Roth Capital Partners is not required to sell any specific number or dollar amount of shares and will act only on a commercially reasonable efforts basis consistent with its normal trading and sales practices; there is no minimum offering amount required to close. The prospectus supplement also discloses that Envoy Medical agreed to reimburse Roth Capital Partners for its legal counsel fees up to $50,000, plus $5,000 per due diligence update session. In connection with sales under the agreement, Roth Capital Partners will be deemed an "underwriter" within the meaning of the Securities Act. Shares will be sold from time to time at prevailing market prices on Nasdaq rather than at a fixed price negotiated in advance, consistent with the at-the-market structure. As of January 16, 2025, Envoy Medical had 21,293,861 shares of Class A Common Stock outstanding, of which approximately 10,702,127 shares were held by non-affiliates. For illustrative purposes only, the prospectus supplement modeled a scenario in which all $15.0 million of shares were sold at $1.50 per share, the last reported Nasdaq closing price on January 16, 2025 (the trading day before the ATM agreement was signed), which would imply roughly 10,000,000 new shares issued, net proceeds of approximately $14.4 million after commissions and estimated offering expenses, and an increase in total shares outstanding to approximately 31,293,861. Because there is no minimum offering amount, the actual number of shares sold, the price at which they are sold, and the resulting gross and net proceeds are not determinable in advance and will depend on market conditions over the life of the ATM program. The prospectus supplement discloses that purchasers in the illustrative $1.50 per share scenario would experience immediate dilution of $1.62 per share, representing the difference between the assumed offering price and Envoy Medical's as-adjusted net tangible book value (deficit) per share as of September 30, 2024 after giving effect to the offering, which the filing states was approximately $(3,499) thousand, or $(0.12) per share, on that pro forma basis. No concurrent share repurchase or buyback was disclosed alongside the offering. Envoy Medical intends to use the net proceeds from the offering for general corporate purposes, which may include working capital, capital expenditures, research and development expenditures, clinical trial expenditures, expansion of business development activities, and other general corporate purposes; the filing also notes proceeds may be used to acquire or invest in complementary products, technologies, or businesses, though no specific acquisition or debt repayment use was identified. No greenshoe or over-allotment option applies to this ATM structure, which is standard for at-the-market programs since shares are issued directly into the market over time rather than in a single underwritten tranche. Fredrikson & Byron, P.A. of Minneapolis, Minnesota serves as legal counsel to Envoy Medical and passed upon the validity of the shares offered. Ellenoff Grossman & Schole LLP of New York, New York represents Roth Capital Partners as the sales agent's legal counsel in connection with the offering. Because the ATM program allows sales over an open-ended period at then-prevailing prices, the prospectus supplement does not provide a specific closing date, a fixed number of shares to be sold, or the ultimate aggregate proceeds that will be raised; these depend on the pace and pricing of sales Envoy Medical and Roth Capital Partners choose to execute under the agreement over its term. No subsequent SEC filing confirming the amount actually sold or the program's completion was identified in this review.

ARCHIMED is acquiring Esperion Therapeutics, Inc., a healthcare company, in an all-cash transaction valued at $1,100,000,000. This is a merger and acquisition transaction in the healthcare sector. The deal remains pending regulatory approval as of the most recent available information. The transaction details are sourced from an SEC EDGAR filing published on May 1, 2026. The specific form type is not identified in the available documentation. The deal is currently in pending regulatory status, meaning all material conditions to closing have not yet been satisfied and the transaction has not closed. Centerview Partners has been retained as exclusive financial advisor to Esperion, the target company, in a lead advisory role. On the acquirer side, Moelis & Company LLC is serving as exclusive financial advisor to ARCHIMED in a lead capacity. For debt financing, investment funds managed by Pharmakon Advisors, LP are providing debt financing for the transaction, positioning Pharmakon in a financing provider role. Goodwin Procter LLP is serving as legal counsel to Esperion Therapeutics. Sidley Austin LLP has been engaged as legal advisor to ARCHIMED. Akin Gump LLP is providing legal advisory services to Pharmakon Advisors, the debt financing provider. The transaction is structured as an acquisition with a disclosed equity value of $1,100,000,000. Debt financing has been committed by Pharmakon Advisors' investment funds, indicating a leveraged component to the overall financing structure. Beyond this confirmation of debt involvement, no further details have been disclosed regarding the specific mix of debt and equity consideration, the amount or terms of any debt facility, interest rates, maturity dates, or other financing terms. Several material facts remain undisclosed or unknown at this time. No expected closing date or regulatory timeline has been provided. The consideration structure (whether cash at close, the role of any escrow, earn-outs, or other adjustments) is not specified. The specific amount of debt financing relative to equity has not been disclosed. Additionally, the regulatory approvals required and the current status of those approvals beyond the general "pending regulatory" designation are not detailed in the available documentation.

This transaction is a subsidiary or asset sale in which AstraZeneca PLC, trading under the ticker AZN, is acquiring FibroGen China from FibroGen. The deal is classified within the healthcare sector, and the disclosed value of the transaction is 160,000,000 dollars. The transaction is sourced from an SEC EDGAR Form 8-K filing published on February 20, 2025. Based on the facts provided, the deal's status is pending regulatory approval. On the financial advisory side, BofA Securities, Inc. is acting as exclusive financial advisor to FibroGen, the seller in this transaction, and is identified as the lead advisor in that capacity. On the legal side, Ropes & Gray LLP is acting as legal advisor to FibroGen, paired with BofA Securities in the same source sentence describing the company's advisory team on this transaction. No financial or legal advisor to AstraZeneca, the acquirer, is identified in the facts provided. Beyond confirming that this is a subsidiary or asset sale with a disclosed value of 160,000,000 dollars, no further detail on the specific assets or subsidiary interests being conveyed, or on any additional consideration structure such as royalties or milestone payments, is included in the facts available. A number of elements of this deal remain undisclosed. No financial or legal advisor to AstraZeneca is named, and no detail is provided on the specific scope of the FibroGen China assets being sold beyond the 160,000,000 dollar disclosed value. The facts also do not specify an expected closing date or what regulatory approvals are required to complete the transaction.

FONAR Corporation, a Melville, New York-based healthcare imaging company trading on Nasdaq under ticker FONR, agreed to be acquired by FONAR, LLC, an entity controlled by an Acquisition Group led by FONAR's own Chief Executive Officer and Chairman, Timothy Damadian, in an all-cash going-private merger. The Agreement and Plan of Merger was signed December 23, 2025 and disclosed in a Form 8-K filed December 30, 2025, with the transaction also structured as a Rule 13e-3 going-private transaction requiring a jointly filed Schedule 13E-3 (originally filed February 26, 2026, with a Final Amendment filed June 3, 2026 reporting the results of the transaction). The transaction closed on June 3, 2026, when FONAR Acquisition Sub, Inc. merged into FONAR, which became a wholly owned subsidiary of Parent, as confirmed in a Form 8-K filed that day. Under the terms of the Merger Agreement, FONAR stockholders received $19.00 in cash per share of common stock and Class B common stock, $6.34 per share of Class C common stock, and $10.50 per share of Class A non-voting preferred stock. According to the Company's press release, the $19.00 common stock price represented a 31.5% premium to the closing share price on the last trading day before the transaction's announcement, a 21.9% premium to the closing price on July 8, 2025 (the last trading day before the Acquisition Group's initial non-binding proposal was announced), and a 39.7% premium to the average closing price over the 90 trading days ended June 30, 2025. A stockholder class action complaint attached as an exhibit to the definitive proxy statement alleged the all-cash merger valued FONAR at approximately $123.5 million; this figure originates from plaintiffs' pleading rather than from a valuation disclosed by the Company or its financial advisor. The Special Committee's independent financial advisor, Marshall & Stevens Transaction Advisory Services LLC, rendered a fairness opinion dated December 23, 2025 concluding that the per-share merger consideration was fair, from a financial point of view, to FONAR's unaffiliated public stockholders. Marshall & Stevens' discounted cash flow analysis, using a weighted average cost of capital of 14.5% (cost of equity of approximately 16.2%, after-tax cost of debt of approximately 4.6%) applied to 10-year management projections, produced an indicated fair market value of FONAR's common equity on a controlling basis of approximately $97.6 million to $104.0 million, implying a per-share value of approximately $14.48 to $15.52 for the common stock, Class B common stock and Class C common stock (on an as-converted basis) -- below the $19.00 per share ultimately paid. According to the DEFM14A's "Background of the Merger" section, Damadian and Chief Operating Officer Luciano Bonanni began considering a going-private transaction as early as December 2021, motivated by the view that the costs of being a Nasdaq-listed public company, including compliance, audit and legal expenses, had become a significant drag on net profits. The Acquisition Group's first non-binding proposal, delivered around July 7, 2025, offered $17.25 per share of common stock (about a 27% premium to the 90-trading-day average price through June 30, 2025); the Special Committee, advised by Marshall & Stevens and its legal counsel Meister Seelig & Fein PLLC, initially countered that this price was inadequate and proposed $22.50 per share. The Acquisition Group subsequently raised its offer to $18.00 per share and then to a final $19.00 per share before the Special Committee agreed to support the deal on December 11, 2025, conditioned on receipt of the Marshall & Stevens fairness opinion. During the negotiation period, an unidentified institutional stockholder referred to in the proxy as "Stockholder 4" sent letters in October and November 2025 expressing non-binding interest in acquiring FONAR for $24.00 per share, calling the Acquisition Group's then-current offer price "inadequate" relative to the Company's reported tangible book value; the Special Committee requested supporting information and documentation from Stockholder 4, which the proxy states was not provided, and no competing transaction materialized. The merger was financed through a combination of new debt, new equity and rollover of existing FONAR securities by Acquisition Group members. Per the announcement 8-K, Parent obtained a committed debt financing facility of $35,000,000 from OceanFirst Bank, N.A., debt subscription commitments of not less than $10,000,000 from other financing sources, and equity subscription commitments (comprising cash and rollover securities) of not less than $45,000,000; the Transaction was not contingent on obtaining this financing. At the closing on June 3, 2026, Parent and the Company (as successor to Merger Sub) entered into a new Credit Agreement with OceanFirst Bank providing a $20 million term loan facility and a $15 million revolving credit facility, secured by substantially all assets of the borrowers and guarantors. Approval required (i) the affirmative vote of a majority of FONAR's capital stock outstanding and entitled to vote, (ii) the affirmative vote of a majority of votes cast by disinterested stockholders, and, out of caution, (iii) satisfaction of the 66 2/3% supermajority threshold under Section 203 of the Delaware General Corporation Law, even though the Company maintained the transaction was not subject to that statute. At a special meeting held May 28, 2026 (record date April 13, 2026, with 15,737,293 total votes and 9,114,425 votes held by non-affiliated holders outstanding and entitled to vote), the Merger Proposal was approved: the Company Stockholder Approval passed 13,124,769 for to 551,079 against; the Disinterested Stockholder Approval passed 3,279,090 for to 551,079 against; and the Section 203 vote passed 6,502,501 for to 551,079 against, as disclosed in a Form 8-K filed May 29, 2026. Upon the Merger Agreement's termination under specified circumstances, FONAR would have owed Parent a termination fee of $450,000, which also covers Parent's documented out-of-pocket deal expenses. Following the closing, FONAR's common stock was suspended from Nasdaq trading, the Company filed to deregister its common stock under the Exchange Act, and four non-employee directors (Ronald G. Lehman II, Richard E. Turk, Jessica Maher and Robert M. Carrino) resigned from the board effective at the effective time of the merger. Legal advisors in the transaction were DLA Piper LLP (US), which represented the Company; Meister Seelig & Fein PLLC, which represented the Special Committee; and Moritt Hock & Hamroff LLP, which represented the Acquisition Group/Buyer entities. Marshall & Stevens Transaction Advisory Services LLC served as financial advisor and independent valuation consultant to the Special Committee; no financial advisor to the Acquisition Group/Buyer side was identified in the filings reviewed.

Fulcrum Therapeutics, Inc. (Nasdaq: FULC) and Slate Medicines, Inc., a biotechnology company developing next-generation migraine therapeutics, announced on August 17, 2026 that they have entered into a definitive agreement to combine in an all-stock merger. The surviving public company will operate as Slate Medicines, Inc. and is expected to trade on Nasdaq under the ticker "SLTE," focusing on Slate's lead candidate SLTE-1009, a clinical-stage subcutaneous anti-PACAP/VIP monoclonal antibody for migraine prevention. Fulcrum's CEO said the deal follows the company's evaluation of strategic alternatives for its rare hematological disease pipeline. This record is sourced from Fulcrum's own 8-K press release (Exhibit 99.1), furnished to the SEC on August 17, 2026. The transaction has received unanimous support from both companies' boards of directors and is structured as a reverse merger paired with a concurrent private placement financing. Wedbush Securities Inc. is serving as exclusive financial advisor to Slate (the accounting acquirer in the combination). Leerink Partners is serving as exclusive financial advisor to Fulcrum. Cooley LLP is serving as legal counsel to Slate. Goodwin Procter LLP is serving as legal counsel to Fulcrum. Under the terms of the merger agreement, pre-merger Fulcrum stockholders are expected to own 5.0% of the combined company and pre-merger Slate stockholders (including investors in the concurrent financing) are expected to own 95.0%, with the split subject to adjustment based on Fulcrum's net cash at closing. Slate has secured commitments for an oversubscribed concurrent private placement of $245 million led by Frazier Life Sciences, with participation from Forbion, RA Capital Management, Deep Track Capital, Foresite Capital, OrbiMed, RTW Investments, and Mingxin Capital, expected to fund operations into 2029. Fulcrum also expects to pay a cash dividend to its pre-merger stockholders equal to the amount by which its net cash exceeds $20.3 million, estimated at approximately $270.0 million. The deal is expected to close in the fourth quarter of 2026, subject to stockholder approval at both companies, Nasdaq listing approval, effectiveness of an S-4 registration statement, and expiration of the Hart-Scott-Rodino waiting period. Not disclosed in this filing: the exact final exchange ratio or adjusted ownership split post-closing, any termination fee, and the specific use of net cash dividend proceeds beyond the stated cap.

DocGo Inc., a publicly traded technology-enabled mobile health and medical transportation company trading under ticker DCGO, has agreed to acquire 100% of Hicuity Health, Inc., a privately held virtual care provider, in a transaction announced August 17, 2026. DocGo disclosed the deal in a Form 8-K filed with the SEC that attached the Agreement and Plan of Merger (dated August 16, 2026) as Exhibit 2.1 and a press release as Exhibit 99.1. Under the agreement, HH Merger Sub, LLC, a subsidiary of DocGo's Ambulnz Holdings, LLC subsidiary, will merge into Hicuity, with Hicuity surviving as a wholly owned subsidiary of Ambulnz. The merger is intended to qualify as a tax-free reorganization under Section 368(a) of the Internal Revenue Code. Hicuity delivers high-acuity virtual clinical care, including Tele-ICU, Virtual Nursing, and Telemetry Monitoring services, to health systems, hospitals, and post-acute facilities. On a trailing 12-month basis, Hicuity generated approximately $65 million in revenue and approximately $4.5 million of adjusted EBITDA, according to DocGo's press release. No single aggregate purchase price or enterprise value figure was disclosed in the filings; instead, consideration is structured as a combination of assumed debt and DocGo stock. DocGo is acquiring Hicuity in exchange for (i) the assumption of Hicuity's existing indebtedness held by Perceptive Credit Holdings IV, LP, estimated at approximately $52 million at closing and now maturing in December 2029, and (ii) equity consideration consisting of a number of DocGo common shares equal to 2.0% of DocGo's fully diluted shares outstanding at closing (the "Closing Stock Consideration"), plus additional "Earnout Shares" equal to 3.5% of DocGo's fully diluted shares outstanding, which vest only if DocGo's common stock achieves a specified market capitalization threshold (publicly described by DocGo as $250 million) within three years of closing, or fully vest automatically upon an above-threshold go-private transaction before expiration. The Earnout Shares are subject to downward-only post-closing adjustment based on final closing indebtedness and transaction expenses; no upward adjustment is permitted. Because the Merger is a "Deemed Liquidation Event" under Hicuity's charter and total consideration is insufficient to satisfy Hicuity's Series F liquidation preference in full, the entire merger consideration is payable solely to Hicuity's Series F Convertible Preferred stockholder; all other classes of Hicuity capital stock, along with all outstanding options and warrants, will be cancelled for no consideration. As part of the transaction, Perceptive Credit Holdings IV, LP (as administrative agent and lender) committed to provide up to an additional $50 million of new senior secured term loan financing to DocGo/Ambulnz, structured as a $12.5 million term loan, a second $12.5 million term loan, and a third $25 million term loan, alongside continuation of $52 million of existing Hicuity term loans. On October 1, 2026, DocGo disclosed in a subsequent Form 8-K that Hicuity and Ambulnz (as co-borrowers), together with DocGo and certain Ambulnz subsidiaries as guarantors, entered into a definitive Amended and Restated Credit Agreement and Guaranty with Perceptive implementing this financing: Term Loan A continues the existing $52 million of Hicuity term loans; Term Loan B is a new $12.5 million facility funded at signing; Term Loan C is a new $12.5 million facility to fund upon consummation of the Merger (or later at DocGo's option); and Term Loan D is a $25 million delayed-draw facility available from the Closing Date through December 31, 2027. The Term Loans bear interest at Term SOFR (with a 3.50% floor) plus a 7.50% margin, with no scheduled amortization before the December 6, 2029 maturity date. In connection with this financing, DocGo also issued Perceptive's administrative agent a warrant to purchase up to 4,000,000 shares of DocGo common stock at an exercise price of $0.5039 per share, fully vested as of the October 1, 2026 issue date and exercisable for ten years. Separately, DocGo terminated its prior undrawn revolving credit facility with Citibank, N.A. on October 1, 2026 in connection with entering into the new credit agreement. Ahead of closing, Ambulnz and Hicuity entered into a Consulting Services Agreement (also dated August 16, 2026) under which Ambulnz manages Hicuity's day-to-day non-clinical operations and funds Hicuity's operating expenses in exchange for a weekly management fee equal to Hicuity's gross revenue collections less operating expenses; this arrangement terminates upon the earlier of closing or termination of the merger agreement. DocGo's October 5, 2026 8-K confirms that the conditions to the Consulting Services Agreement were satisfied and Ambulnz began managing Hicuity's non-clinical operations effective October 1, 2026, but it explicitly describes the Merger's closing as still "pending" as of that filing date; no closing 8-K has been filed. DocGo's CEO, Lee Bienstock, said the transaction "took a major leap forward" in the company's evolution "into the premier provider of virtual, remote, and in-home healthcare at any address," adding that "Hicuity brings technology-enabled acute and critical care telemedicine capabilities, serving a diverse portfolio of health systems across the United States," and that integrating Hicuity's offering would help "create one of the most innovative healthcare delivery platforms in the industry" by matching "the right clinician with the right patient at the right time in the right setting," bridging patient care "from the hospital to the home." DocGo's CFO, Norm Rosenberg, said the pending acquisition "represents not only a significant growth opportunity with numerous cost synergies, but will also create a combined entity with much greater financial liquidity," and credited Perceptive Advisors as "a healthcare lending partner of the caliber" willing to commit up to $50 million of additional debt financing "if needed." No specific dollar figure or percentage for the referenced cost synergies was disclosed in the filings. DocGo stated in the same press release that its full-year 2026 financial guidance (revenue of $305-$310 million and adjusted EBITDA of negative $17 million to negative $22 million) does not include any contribution from the Hicuity acquisition, because the transaction had not yet closed. The merger agreement contains customary closing conditions, including accuracy of representations and warranties, compliance with covenants, absence of governmental orders prohibiting the transaction, delivery of closing deliverables, and Ambulnz's entry into a definitive credit agreement assuming Hicuity's indebtedness (since satisfied via the October 1, 2026 credit agreement). Ambulnz will procure a representations-and-warranties insurance policy as the primary source of recovery for breaches of Hicuity's representations and warranties. The agreement may be terminated by mutual consent or by either party for an uncured material breach, material failure to perform obligations, or a final non-appealable governmental order prohibiting the transaction. No termination fee was disclosed in the filings reviewed. The agreement is governed by Delaware law. Norton Rose Fulbright is acting as legal counsel to DocGo for the transaction. TD Cowen is acting as exclusive financial advisor to Hicuity Health, and Stradling Yocca Carlson Rauth is acting as Hicuity Health's legal counsel, according to DocGo's press release.

Hologic, Inc., a Nasdaq-listed (HOLX) healthcare sector company, agreed on October 21, 2025 to be acquired by affiliates of investment funds managed by Blackstone Inc. and TPG Global, LLC in an all-cash-plus-CVR going-private transaction. The transaction was valued at up to $79.00 per share, comprising $76.00 per share in cash plus a non-tradable contingent value right (CVR) of up to $3.00 per share, representing an enterprise value of up to $18.3 billion (based on 228 million diluted shares, $2.2 billion of cash and short-term investments, and $2.5 billion of debt as of September 27, 2025). The aggregate purchase price represented approximately a 46 percent premium to Hologic's closing stock price on May 23, 2025, the last full trading day before media reports of a possible transaction surfaced. The deal also included significant minority equity investments from a wholly owned subsidiary of the Abu Dhabi Investment Authority (ADIA) and an affiliate of GIC alongside Blackstone and TPG. Stephen P. MacMillan, Hologic's Chairman, President and CEO, said the transaction marked "an exciting new chapter for Hologic" and that Blackstone and TPG's "resources, expertise and commitment to women's health" would "help accelerate our growth." Ram Jagannath, a Senior Managing Director at Blackstone, called Hologic "an outstanding global leader in advancing women's health" with a "longstanding reputation for groundbreaking and high-quality medical device and diagnostic products." John Schilling, Co-Managing Partner of TPG Capital, said Hologic represented "a compelling opportunity to draw upon our deep thematic expertise to support the development of next-generation solutions." The non-tradable CVR entitled each Hologic stockholder to up to two payments of up to $1.50 each, contingent on Hologic's Breast Health business achieving specified global revenue milestones in fiscal years 2026 and 2027. Per the definitive merger proxy, the CVR revenue targets were set at $1,571,844,377 for the fiscal 2026 milestone period and $1,666,256,283 for the fiscal 2027 milestone period, matching management's internal Breast Health revenue forecasts for those years. The proxy also disclosed that a stop-ship issue involving the company's Brevera biopsy device needles, which arose after the October 20, 2025 signing, made the Board believe the 2026 CVR milestone would be more challenging to achieve. Goldman Sachs & Co. LLC, Hologic's financial advisor, rendered a fairness opinion to the Board and performed an illustrative discounted cash flow analysis using discount rates of 8.5% to 10.5% and perpetuity growth rates of 2.0% to 3.0% (implying terminal year EBITDA exit multiples of 8.5x to 13.2x), which produced a range of illustrative present values of $66.67 to $99.09 per share, bracketing the agreed $76.00 upfront cash price. The merger agreement included a 45-day go-shop period during which Hologic and its advisors could solicit superior proposals; per the proxy, the go-shop period ended with the company not having received any competing acquisition proposal. Parent funded the merger consideration through a combination of debt and equity financing. Blackstone and TPG obtained a debt financing commitment letter from Citi, Bank of America, Barclays, Royal Bank of Canada and SMBC, together with equity commitment letters from Blackstone- and TPG-advised funds. Goldman Sachs & Co. LLC served as exclusive financial advisor to Hologic, and Wachtell, Lipton, Rosen & Katz served as legal counsel to the company. Citi served as exclusive financial advisor to the Blackstone-and-TPG-led consortium, with Kirkland & Ellis LLP as legal counsel and Ropes & Gray as healthcare regulatory counsel to the sponsors. The merger agreement provided for a Company termination fee of $540,000,000 in most circumstances (reduced to $225,000,000 if Hologic terminated to accept a superior proposal from an "excluded party" that emerged during the go-shop period), and a reverse termination fee payable by Parent of $900,000,000 if the deal failed to close due to parent-side breach or failure of debt/equity financing. Hologic's stockholders approved the merger agreement at a special meeting held February 5, 2026, with holders of 178,777,739 shares (representing the vast majority of the 179,046,131 shares voting) in favor, versus 151,271 against and 117,121 abstaining; a separate, non-binding advisory vote on golden-parachute compensation was not approved. As of late January 2026, Hologic also disclosed several disclosure-based stockholder lawsuits and demand letters challenging the adequacy of the proxy statement, which the company stated it believed were without merit. The transaction closed on April 7, 2026. Pursuant to the Agreement and Plan of Merger dated October 21, 2025, Hopper Merger Sub Inc. merged with and into Hologic, with Hologic surviving as a wholly owned subsidiary of Hopper Parent Inc., an entity affiliated with Blackstone and TPG. At closing, each outstanding Hologic share was converted into the right to receive $76.00 in cash plus one CVR. The total cash consideration payable to Hologic equityholders was approximately $17.3 billion. In connection with closing, Hologic repaid and terminated its existing credit agreement, deposited funds to redeem all $400 million of its outstanding 4.625% Senior Notes due 2028 and all $950 million of its outstanding 3.250% Senior Notes due 2029, entered into a CVR agreement with Equiniti Trust Company, LLC as rights agent, delisted its common stock from Nasdaq, and amended and restated its certificate of incorporation. Stephen P. MacMillan resigned as CEO and from the board, and Jos (Joe) E. Almeida was appointed CEO and a director; eight other legacy directors also resigned from the board.

This deal involves RadNet, Inc. (ticker RDNT), a healthcare-sector company, as the acquirer of iCAD, Inc., in an all-stock merger. The transaction falls under the M&A product group, and its disclosed value is $103,000,000. The facts are sourced from an 8-K filing with the SEC via EDGAR, published April 15, 2025. The deal's status is pending regulatory, indicating it had not yet closed as of that filing. Only one financial advisor is disclosed: Piper Sandler & Co., which is serving as financial advisor to iCAD (the target) and is designated lead. The source sentence states that Piper Sandler & Co. is serving as financial advisor to iCAD and Dentons US LLP is serving as iCAD's legal counsel. No financial advisor is named for the acquirer, RadNet, in the facts provided. Legal advisors are disclosed for both sides. Dentons US LLP is serving as iCAD's (the target's) legal counsel, per the same source sentence naming Piper Sandler. On the acquirer side, both Perkins Coie LLP and Reed Smith LLP are serving as legal counsel to RadNet in connection with the transaction, per the source sentence naming both firms together. Beyond classifying the transaction as an all-stock merger valued at $103,000,000, the facts block does not specify the exchange ratio or the pro forma ownership split between RadNet and iCAD shareholders. Several facts are not disclosed in this record. No financial advisor is named for the acquirer, RadNet. No expected closing date is given, and the facts block does not specify the exchange ratio for the stock merger or clarify the respective roles of RadNet's two legal advisors, Perkins Coie LLP and Reed Smith LLP, relative to one another.

Indaptus Therapeutics, Inc., a healthcare company trading under ticker INDP on the Nasdaq Capital Market, has established an at-the-market (ATM) equity offering program for shares of its common stock with an aggregate offering price of up to $100,000,000. On August 28, 2026, the Company entered into an Amended and Restated At the Market Offering Agreement with H.C. Wainwright & Co., LLC, which amends, restates in its entirety, and supersedes the original At the Market Offering Agreement dated June 1, 2022 between the Company and Wainwright. The $100,000,000 maximum applies only to shares sold on or after the execution date of the new agreement; shares previously sold under the original 2022 agreement do not count toward the new limit. The Company filed a prospectus supplement dated August 31, 2026, together with an accompanying base prospectus dated August 20, 2025, as part of its shelf registration statement on Form S-3 (File No. 333-289573), which was declared effective on August 20, 2025. On September 4, 2026, the Company filed Amendment No. 1 to that prospectus supplement solely to correct a clerical error in the mathematical calculations in the dilution section; it states that as of September 4, 2026, no shares of common stock had yet been sold under the Offering Agreement. No subsequent SEC filing identified in this review discloses any shares having been sold under the ATM program since that date. Under the agreement, Wainwright acts as sales agent and/or principal and will use commercially reasonable efforts, consistent with its normal trading and sales practices, to sell shares into the Nasdaq Capital Market or another existing U.S. trading market at prevailing market prices, in negotiated transactions, or directly to Wainwright as principal, as the Company directs through sales notices specifying amount and minimum price. There is no minimum offering amount required to close the program, so the actual total amount sold, commissions, and proceeds are not determinable in advance. Settlement occurs on the second trading day following each sale through The Depository Trust Company. The Company will pay Wainwright a placement fee equal to 3.0% of the gross sales price of shares sold, and Wainwright is deemed an "underwriter" within the meaning of the Securities Act, with its compensation deemed underwriting commissions or discounts. The Company also agreed to reimburse Wainwright up to $50,000 for its legal counsel's fees related to the offering, plus up to $5,000 per quarterly bringdown and $3,500 per annual bringdown for ongoing diligence-related legal costs. The prospectus supplement states the Company intends to use net proceeds for working capital, general corporate purposes, and strategic initiatives, including potential acquisitions (none identified as of the filing), investments, and research collaborations, with management retaining broad discretion over allocation; no specific debt repayment or identified acquisition use is disclosed. For illustrative dilution purposes, the prospectus supplement (as corrected by Amendment No. 1) assumed a hypothetical full draw of $100,000,000 at $1.14 per share, the last reported Nasdaq closing price on August 26, 2026, implying approximately 87,719,298 shares if the entire program were sold at that single price (actual sales would occur at varying prices over time). Based on 133,242,324 shares outstanding as of June 30, 2026, a full illustrative draw at that assumed price would represent dilution of roughly 66% of pre-offering shares outstanding. As corrected, net tangible book value as of June 30, 2026 was approximately $11.4 million, or $0.09 per share; pro forma net tangible book value after a hypothetical full $100,000,000 draw at $1.14 per share was calculated at approximately $108.3 million, or $0.49 per share, representing an immediate increase of $0.40 per share to existing stockholders and immediate dilution of $0.65 per share to new investors in the illustrative scenario. (The original August 31, 2026 prospectus supplement had understated net tangible book value, pro forma figures, and per-share dilution due to a clerical calculation error later corrected in Amendment No. 1.) No greenshoe or over-allotment option applies to this program, as ATM offerings of this type do not use such mechanisms; sales occur incrementally over time rather than in a single underwritten tranche. McCarter & English, LLP served as legal counsel to Indaptus Therapeutics and issued an opinion, filed as Exhibit 5.1 to the Form 8-K, on the validity of the shares issuable under the Sales Agreement. Haynes and Boone, LLP, of New York, New York, served as counsel to Wainwright in connection with the offering, as disclosed in the "Legal Matters" section of the prospectus supplement. Separately, on September 8, 2026, Indaptus entered into a Stock Purchase Agreement for an unregistered private placement of 20,338,974 shares of common stock for aggregate gross proceeds of approximately $24.0 million, priced at the "Nasdaq Minimum Price" plus $0.015 per share; that transaction is distinct from, and not part of, the $100,000,000 ATM program described above and is not the subject of this deal record. Several details remain undisclosed: the actual number of shares sold or proceeds raised to date under the ATM program (none confirmed as of the most recent prospectus amendment on September 4, 2026), any specific pricing of individual ATM sales, and any expected timeline for drawing down the full $100,000,000. The nature of the "pending regulatory" status and any specific conditions to further draws are not specified in the filings reviewed.

This record concerns Inotiv, Inc., a healthcare-sector company, as the issuer in a Chapter 11 plan of reorganization. The transaction falls under the restructuring product group, and its disclosed value is not stated in the source document. The facts are sourced from an 8-K filing with the SEC via EDGAR, published July 16, 2026. The deal's status is pending regulatory, indicating the restructuring process had not yet concluded as of that filing. Only one financial advisor is disclosed: Perella Weinberg Partners, which is serving as investment banker to the company (Inotiv) and is designated lead. The source sentence states that Inotiv is advised in this matter by Ropes & Gray LLP as legal counsel, Perella Weinberg Partners as investment banker, and FTI Consulting as financial and communications advisor, indicating FTI Consulting also plays an advisory role to the company though it is not separately broken out as a distinct financial-advisor entry with lead status in the facts block. Multiple legal advisors are disclosed across different constituencies. Ropes & Gray LLP serves as legal counsel to the issuer, Inotiv. The Noteholder Ad Hoc Group, a creditor constituency, is advised by Paul, Weiss, Rifkind, Wharton & Garrison LLP as legal counsel. Separately, the Prepetition First Lien Lenders, another creditor constituency, are advised by Davis Polk & Wardwell LLP as legal counsel and BRG as financial advisors, per the source sentence describing that lender group's advisory team. Beyond identifying this as a Chapter 11 plan of reorganization, the facts block does not provide the specific terms of the plan, such as recovery percentages for different creditor classes or the treatment of existing equity. Several facts are not disclosed in this record. The transaction's dollar value is not stated. No expected timeline for plan confirmation is given, and the facts block does not specify BRG's lead-versus-non-lead status as financial advisor to the Prepetition First Lien Lenders, nor FTI Consulting's lead status on the company side.

This deal involves Inozyme Pharma, Inc., a healthcare-sector company, as the target of an acquisition by BioMarin Pharmaceutical Inc. (ticker BMRN). The transaction is an M&A deal structured as a tender offer, and its disclosed value is $270,000,000. The record draws on a substantial number of SEC EDGAR filings: an SC TO-T published June 2, 2025; a filing of unknown form type published May 16, 2025; two 8-K filings both published May 16, 2025 and an additional 8-K published July 1, 2025; a second unknown-form filing published May 16, 2025; and an SC 14D9 published June 2, 2025. The deal's status is closed, indicating the tender offer was completed. The facts block names two financial advisors, each designated as lead on their respective side. Goldman Sachs & Co. LLC acted as exclusive financial advisor to BioMarin, the acquirer, while Cooley LLP served as BioMarin's legal counsel, per the source language that these two firms were advising the acquirer in tandem. On the target side, Centerview Partners LLC acted as exclusive financial advisor to Inozyme, with Goodwin Procter LLP serving as Inozyme's legal counsel, as stated in the corresponding source sentence. These advisor-role pairings (financial advisor plus legal counsel per side) recur multiple times across the underlying source documents, reflecting that the same relationship was reported in more than one filing. On the legal side, Cooley LLP is confirmed as legal advisor to the acquirer, BioMarin, and Goodwin Procter LLP is confirmed as legal advisor to the target, Inozyme, consistent with the pairings described above. Beyond identifying the transaction as a tender offer with a $270,000,000 disclosed value, the facts block does not provide additional detail on the offer price per share, the proration mechanics, or any other structural terms of the tender offer. Notably absent from the record are details such as the specific per-share tender price, the percentage of shares sought or tendered, and any conditions to closing. Since the deal's status is listed as closed, the disclosed value and advisor roles described above represent the full extent of what the source material provides about how the transaction concluded.

Intellia Therapeutics, Inc., a healthcare company trading under ticker NTLA, entered into a Credit Agreement on September 4, 2026 (the Closing Date) establishing a five-year senior secured credit facility of up to $400 million. The lenders are OrbiMed Royalty & Credit Opportunities IV, LP and OrbiMed Royalty & Credit Opportunities V, LP, with OrbiMed Royalty & Credit Opportunities V, LP acting as administrative agent. The facility was disclosed in a Form 8-K (Items 1.01, 2.03, 7.01 and 9.01) filed with the SEC on September 4, 2026, which included a press release as Exhibit 99.1. The facility is structured in multiple tranches rather than as a single draw. It includes an initial term loan of $75 million funded at closing; a potential additional $75 million draw at Intellia's option upon FDA approval of its biologics license application (BLA) for lonvoguran ziclumeran (lonvo-z) prior to a certain date; three potential additional $40 million draws at Intellia's option upon achieving certain revenue targets for lonvo-z prior to certain dates (totaling up to $120 million, consistent with the press release's reference to additional tranches totaling up to $225 million tied to the FDA-approval and revenue milestones); a potential additional $30 million draw at Intellia's option upon achieving an equity fundraising target prior to a certain date; and an uncommitted additional incremental facility of up to $100 million subject to mutual agreement among Intellia and the lenders. The press release additionally characterizes the facility as non-dilutive. The Credit Facility matures on September 4, 2031. Loans bear interest, payable monthly, at a rate per annum equal to the greater of (a) 3.00% or (b) the one-month SOFR rate applicable to the period, plus an applicable margin of 6.15%. Intellia is also required to pay customary commitment, administrative, undrawn amount and facility fees. Intellia may prepay amounts owed prior to the maturity date subject to a repayment premium or exit fee, as applicable, plus accrued interest on amounts repaid or prepaid; the facility is also subject to customary mandatory prepayments from proceeds of indebtedness and certain asset sales and casualty events. The 8-K does not specify the exact dollar amount or percentage of the repayment premium or exit fee. Proceeds of the Credit Facility are to be used for Intellia's working capital needs and general corporate purposes. The 8-K does not disclose that this facility refinances any prior specific credit facility; no prior facility is named. All obligations under the Credit Agreement are secured on a first-priority basis, subject to certain exceptions, by security interests in substantially all of Intellia's assets, including its intellectual property. The Credit Agreement is not covenant-lite: it contains customary financial covenants, including a requirement to maintain liquidity of at least $50 million in controlled accounts until FDA approval of the lonvo-z BLA, and, thereafter, a requirement to either achieve certain revenue targets, maintain certain market capitalization thresholds, or maintain outstanding loan principal in cash equivalents in controlled accounts. It also contains negative covenants that, subject to certain exceptions, restrict Intellia's ability to incur additional indebtedness, grant liens, make investments (including acquisitions), effect mergers or consolidations, engage in asset sales and licensing transactions, pay dividends, terminate or modify certain material agreements, and pay subordinated indebtedness, among other customary restrictions. Exceptions to the indebtedness and lien covenants permit Intellia to enter into synthetic royalty transactions, subject to certain restrictions in the Credit Agreement. The Credit Agreement contains customary events of default, including payment defaults, material inaccuracy of representations and warranties, covenant defaults, bankruptcy and insolvency proceedings, cross-defaults to certain other agreements, judgments against Intellia and its subsidiaries, and change of control. TD Cowen acted as exclusive financial advisor to Intellia on the transaction. Goodwin Procter LLP acted as legal advisor to Intellia. Covington & Burling LLP acted as legal advisor to OrbiMed, confirming OrbiMed as the lender/creditor side of the transaction (via its affiliated funds OrbiMed Royalty & Credit Opportunities IV, LP and V, LP, the latter also serving as administrative agent). The 8-K states that the full Credit Agreement itself had not yet been filed as of the September 4, 2026 report; Intellia disclosed that it will be filed as an exhibit to its Quarterly Report on Form 10-Q for the quarter ending September 30, 2026. As of this update, that 10-Q has not yet been filed with the SEC (the most recent 10-Q on file is for the quarter ended June 30, 2026, filed August 6, 2026), so the complete text of the Credit Agreement, including the precise pricing grid (if any), full definitions of the revenue/market-cap thresholds, and the exact repayment premium or exit fee schedule, remains undisclosed. The deal status remains announced; no closing, draw, or termination beyond the initial $75 million funded at the Closing Date has been confirmed in subsequent filings.

Medtronic plc announced on May 13, 2022 that it had completed its acquisition of Intersect ENT, adding Intersect ENT's PROPEL and SINUVA bioabsorbable, steroid-eluting sinus implant product lines, associated intellectual property, and its Menlo Park, California facility to Medtronic's ear, nose and throat portfolio. The release notes the deal had first been announced on August 6, 2021, and that a former Intersect ENT brand, Fiagon, was divested simultaneously at close and was not included in Medtronic's acquisition. This record is sourced from an Exhibit 99.1 press release furnished with Intersect ENT's Form 8-K filed May 13, 2022, announcing the completed closing of the acquisition rather than its original signing. Perella Weinberg Partners LP served as financial advisor to Medtronic, the acquirer, per the release's statement that "The Medtronic financial advisor for the transaction is Perella Weinberg Partners LP, with Ropes & Gray LLP acting as legal advisor." Goldman Sachs & Co. LLC served as financial advisor to Intersect ENT, the target, as stated in "Intersect ENT's financial advisor is Goldman Sachs & Co. LLC, with Cooley LLP acting as legal advisor." No lead designation is specified for either side since each company retained a single financial advisor. On the legal side, Ropes & Gray LLP represented Medtronic and Cooley LLP represented Intersect ENT. The release describes the strategic rationale (expanding Medtronic's chronic rhinosinusitis treatment portfolio) and notes that Intersect ENT employees joined Medtronic as part of the closing, but it does not describe the consideration structure (cash, stock, or mix) in this particular exhibit. Not disclosed in the sourced document is the transaction's purchase price or valuation multiple, the original August 2021 signing date's financial terms, or any regulatory conditions that were satisfied prior to this closing announcement.

This record covers a Chapter 11 transaction support agreement in the healthcare sector, with Invitae Corp as issuer. The product group is restructuring. The disclosed value is not stated in the source document(s). The facts are sourced from an 8-K filed with the SEC via EDGAR, published on February 14, 2024. The deal's current status is pending regulatory review. One financial advisor is identified, representing the creditors' side: Perella Weinberg Partners LP, serving as investment banker. The source sentence is drawn from a fee reimbursement provision: "...reasonable and documented fees and expenses when due of the Consenting Stakeholders... including the reasonable and documented fees and expenses of (a) Sullivan & Cromwell LLP, as legal counsel, (b) Hogan Lovells US LLP, as legal counsel, (c) Wollmuth Maher & Deutsch LLP, as legal counsel (d) Perella Weinberg Partners LP, as investment banker... necessary or advisable to represent the interests of the Required Consenting Stakeholders." No lead designation is specified for Perella Weinberg in this capacity. Three legal advisors are identified, all representing the creditors (the Consenting Stakeholders) per the same fee reimbursement provision: Sullivan & Cromwell LLP, Hogan Lovells US LLP, and Wollmuth Maher & Deutsch LLP each served as legal counsel to the Required Consenting Stakeholders. Beyond the classification of this matter as a Chapter 11 transaction support agreement, no further detail on the specific restructuring terms, such as treatment of claims or the capital structure post-emergence, is included in the facts provided. Several items are not disclosed in this record: the transaction value is not stated, no financial or legal advisor to the company (Invitae) itself, as distinct from the creditors, is identified in the facts provided, the specific terms of the transaction support agreement are not given, and no expected emergence or closing date is given beyond the pending-regulatory status.

KALA BIO, Inc., a healthcare sector company trading under the ticker KALA, entered into an At The Market Offering Agreement (the Sales Agreement) with H.C. Wainwright & Co., LLC on January 8, 2026, providing for the sale and issuance of shares of common stock, par value $0.001 per share, having an aggregate offering price of up to $15,000,000. The transaction was documented in a Form 8-K filed with the SEC on January 8, 2026, and in a prospectus supplement on Form 424B5, also dated and filed January 8, 2026, under the company's existing shelf registration statement on Form S-3 (File No. 333-270263), initially filed March 3, 2023 and declared effective May 11, 2023. The prospectus supplement discloses that shares may be sold from time to time through Wainwright acting as sales agent or principal, using any method permitted under Rule 415(a)(4) of the Securities Act, including ordinary brokerage transactions on Nasdaq, sales to or through a market maker, or, with KALA's prior written approval, privately negotiated or block transactions. Wainwright is not obligated to sell any specific number or dollar amount of shares, and the gross sales price will be the prevailing market price on Nasdaq at the time of each sale. For illustrative purposes only, the prospectus supplement calculates that the full $15,000,000 would equate to approximately 24,150,700 shares at an assumed offering price of $0.6211 per share, the last reported Nasdaq sale price on January 2, 2026, which would bring shares outstanding to approximately 52,000,425 from a base of 27,849,725 shares outstanding as of December 31, 2025 (before giving effect to outstanding options, pre-funded warrants, warrants, RSUs, and convertible preferred stock). The cover page separately notes that the last reported sale price on January 7, 2026, the trading day before the Sales Agreement was signed, was $0.665 per share. Because the ATM is a continuous program with sales made at prevailing market prices rather than a single priced transaction, the filings do not disclose a discrete premium or discount to a specific reference price, nor do they disclose any greenshoe or over-allotment option, which is not a standard feature of ATM programs. Wainwright will be entitled to a sales commission equal to 3.0% of the gross sales price of shares sold under the Sales Agreement, and KALA has agreed to reimburse Wainwright up to $50,000 for legal fees and expenses incurred in connection with entering into the agreement, plus up to $3,500 per due diligence update on each representation date. In connection with the offering, Wainwright will be deemed an "underwriter" within the meaning of the Securities Act, and its compensation will be deemed underwriting commissions or discounts. KALA has agreed to provide customary indemnification and contribution rights to Wainwright. On use of proceeds, KALA states it currently intends to use net proceeds for general corporate purposes, including working capital, pending investment in short- and intermediate-term capital preservation instruments. However, the prospectus supplement also discloses mandatory proceeds sweeps tied to other financing arrangements: under the terms of a Loan Agreement, in the event KALA or its subsidiary obtains debt financing or receives proceeds from the sale of securities or other indebtedness, 25% of such proceeds must be used to repay the loan, due on the one-year anniversary of receipt and bearing 15% simple interest per annum; and under an Oxford Settlement Agreement, 10% of proceeds from the sale and issuance of equity securities on or after a defined shareholder meeting date must be paid directly to Oxford as collateral agent, without deduction, up to a maximum of $1,000,000. Haynes and Boone, LLP, New York, New York, passed on the validity of the shares for KALA as issuer's counsel and delivered the legal opinion filed as Exhibit 5.1 to the 8-K. Wainwright was represented in the offering by Ellenoff Grossman & Schole LLP, New York, New York, as disclosed in the prospectus supplement's Legal Matters section. The company's Form 10-Q for the quarter ended March 31, 2026 (filed May 15, 2026) confirms the ATM Agreement remained in place with $15.0 million of common stock still eligible for sale as of that filing date, and describes the ATM as one of several financing alternatives (alongside private placements and asset monetization) the company was evaluating to extend its cash runway into the second quarter of 2027; it does not disclose any shares having yet been sold or proceeds raised under this specific ATM program. No pricing 8-K, free-writing prospectus, or closing/termination announcement specific to actual sales under the January 2026 Sales Agreement has been identified. A separate, later at-the-market prospectus supplement was filed by KALA on July 22, 2026 under a different, newly effective shelf registration statement (File No. 333-295667); because that filing relates to a distinct registration statement and Sales Agreement rather than an update to the January 8, 2026 program, it is treated as a separate transaction and is not incorporated into this summary. The deal remains in announced status, with no explicit confirmation found that the January 2026 ATM program has closed, been fully utilized, or been terminated.

Amneal Pharmaceuticals, Inc., a biopharmaceutical company trading under ticker AMRX, has completed its acquisition of Kashiv BioSciences, LLC, a vertically integrated biosimilars developer and manufacturer, after entering into a Membership Interest Purchase Agreement dated April 21, 2026 and obtaining stockholder approval on July 31, 2026. The acquisition closed on August 10, 2026, with Amneal purchasing 100% of Kashiv's outstanding membership interests. Because Kashiv is owned by members of the Amneal Group, including Amneal's Co-Founders and Co-Chief Executive Officers Chirag Patel and Chintu Patel, the transaction was structured and negotiated as a related-party deal, delegated to an Independent (Conflicts) Committee of Amneal's board and subjected to a majority-of-the-disinterested-stockholders vote in addition to standard approval of the stock issuance. "The completion of this acquisition marks a pivotal step in Amneal's strategy to become America's #1 Affordable Medicines company," said Chirag Patel at closing. "With this acquisition, we have created an integrated biosimilars business that can launch multiple biosimilars each year and extends our growth profile into the next decade." At signing, Chirag Patel said the deal makes Amneal "a fully integrated global biosimilars leader at the forefront of the next wave of U.S. affordable medicines," while Chintu Patel said combining "Kashiv's deep R&D and manufacturing capabilities with our commercial strength" creates a platform to deliver "a strong and consistent cadence of biosimilar launches." Kashiv's CEO, Dr. Sandeep Athalye, called it an opportunity to combine "highly complementary portfolio and capabilities with Amneal at this critical inflection point for the biosimilar market," noting the deal builds on a collaboration of more than ten years between the companies. Amneal said the acquisition provides access to a market facing more than $300 billion of projected global biologics loss-of-exclusivity over the next decade and that it expects more than 12 commercial biosimilars by 2030 with over 20 more in the pipeline. Under the terms of the Purchase Agreement, Amneal paid Kashiv's sellers $375 million in cash (subject to customary adjustments for cash, interim operating funding, indebtedness, transaction expenses and working capital) plus 28,942,098 shares of Class A common stock (originally 28,942,108 shares before a fractional-share adjustment), which the companies valued at signing at approximately $375 million, for combined upfront consideration of roughly $750 million. Sellers are also eligible for up to an additional $350 million in contingent payments tied to the achievement of U.S. regulatory milestones for up to six designated Kashiv product candidates, plus contingent royalty payments over a 12-year period following closing equal to 25% of the amount by which annual aggregate gross profits for certain products exceed specified hurdle amounts. A portion of the cash consideration was funded through a new $350 million incremental term loan provided by Bank of America, N.A. under Amendment No. 4 to Amneal LLC's existing Term Loan Credit Agreement with JPMorgan Chase Bank, N.A. as administrative agent. Goldman Sachs & Co. LLC, financial advisor to the Independent Committee, rendered a fairness opinion dated April 21, 2026 covering the cash, stock, milestone and royalty consideration. In its discounted cash flow analysis, using discount rates of 11.0% to 13.0% and perpetuity growth rates of 0.0% to 1.5% (implying terminal-year EBITDA exit multiples of 5.6x to 7.8x), Goldman Sachs derived an illustrative intrinsic enterprise value for Kashiv of between $1.6 billion and $2.1 billion excluding synergies, and between $1.9 billion and $2.3 billion including Amneal's estimated cost synergies. Separately, Goldman Sachs calculated a risk-adjusted net present value of the full consideration package, finding the $350 million of contingent milestone payments (probability-weighted at 20% to 93% depending on product, discounted at an estimated 12.0% weighted average cost of capital) had a present value of approximately $125 million as of December 31, 2025. Amneal disclosed that the transaction is "highly synergistic," with $400 million to $500 million in expected financial benefits through elimination of upcoming milestone and royalty obligations through 2030 and incremental tax and structural benefits over time, and said it expects minimal impact to its leverage profile with a path to deleveraging below 3x net leverage by 2028. The proxy statement's negotiation history shows the deal terms were substantially reduced from Kashiv's initial, non-binding June 2025 proposal, which had sought $900 million of upfront consideration ($250 million cash and $500 million stock, with Kashiv's existing term loan not deducted from the purchase price), up to $1.125 billion in success-based milestones, and a 10-year, 7.5%-of-net-sales royalty on Kashiv's first seven pipeline programs. On the Independent Committee side, Goldman Sachs & Co. LLC served as financial advisor and Richards, Layton & Finger, P.A. and Blue Raven LLP served as outside legal counsel; The Boston Consulting Group, Inc. and InterPharmaLink AG were also engaged as industry consultants during the Committee's review. Simpson Thacher & Bartlett LLP served as legal counsel to Amneal, with KPMG US serving as Amneal's outside tax, finance and accounting advisor. On the Kashiv/seller side, J.P. Morgan Securities LLC served as financial advisor, Holland & Knight LLP served as legal counsel, and Dhinal Shah Associates served as an India-based advisor. Ernst & Young LLP audited Amneal's financial statements and Grant Thornton LLP audited Kashiv's financial statements. Innisfree M&A Incorporated acted as Amneal's proxy solicitor for the special stockholder meeting. At a July 31, 2026 special meeting, Amneal stockholders approved both the Transaction Proposal and the Stock Issuance Proposal. Of 319,331,346 shares outstanding, 288,567,159 were present or represented by proxy, including 138,987,985 shares held by disinterested stockholders; the Transaction Proposal (requiring majority approval of disinterested stockholders under DGCL Section 144 safe-harbor standards) passed with 138,265,079 votes for, 655,759 against and 67,147 abstentions, and the Stock Issuance Proposal passed with 286,714,072 votes for, 1,791,016 against and 62,071 abstentions. The agreement was not subject to any financing condition, and the parties had set an outside date of November 17, 2026 (automatically extendable to January 12, 2027 if only certain regulatory conditions remained outstanding), though the deal closed well ahead of that date. As required by the agreement, Amneal also issued the stock consideration in an unregistered placement under Section 4(a)(2) of the Securities Act and has agreed to file a Form S-3 resale registration statement for those shares. Amneal stated it intends to file Kashiv's historical and pro forma financial statements required under Item 9.01 by amendment within 71 days of the closing report; those statements were not yet available as of the closing 8-K and so detailed combined/pro forma income statement or balance sheet figures are not yet disclosed.

This record concerns Kestra Medical Technologies, Ltd. (ticker KMTS), a healthcare-sector company, as the issuer in a follow-on common share offering. The transaction falls under the equity capital markets (ecm) product group, and its disclosed value is $138,000,000. The facts are sourced from a Form 424B4 filing with the SEC via EDGAR, published December 3, 2025. The deal's status is pending regulatory, indicating the offering process had not yet fully concluded as of that filing. Five financial advisors, all acting as underwriters for the issuer, are disclosed. BofA Securities is named with a lead designation, while Piper Sandler, J.P. Morgan, Goldman Sachs & Co. LLC, and Wells Fargo Securities are also listed as underwriters. The source sentence underlying all five entries is simply the list of names as they appeared in the filing: "BofA Securities Piper Sandler J.P. Morgan Goldman Sachs & Co. LLC Wells Fargo Securities," reflecting a standard underwriter cover-page listing rather than a narrative description of each bank's specific role (e.g., bookrunner versus co-manager) beyond BofA's designated lead status. No legal advisors are identified in the facts block for this transaction. Beyond identifying this as a follow-on common share offering with a disclosed value of $138,000,000, the facts block does not specify the offering price per share, the number of shares offered, or the use of proceeds. Several facts are not disclosed in this record. No legal advisors are named for the issuer. The facts block does not distinguish between bookrunner and co-manager roles among the five named underwriters beyond BofA Securities's lead designation, and no expected closing date for the offering is given.

This transaction is a stock-for-stock reverse merger in which Korro Bio, Inc., trading under the ticker KRRO, is combining with Frequency Therapeutics, Inc. The deal is classified within the healthcare sector, and the disclosed value of the transaction is not stated in the source document. The transaction is sourced from an SEC EDGAR Form S-4 filing published on July 27, 2023. Based on the facts provided, the deal's status is pending regulatory approval. On the financial advisory side, Cowen and Company, LLC served as financial advisor to Frequency Therapeutics and is identified as the lead advisor in this transaction. The source material is drawn from a consent letter dated July 13, 2023, addressed to the Board of Directors of Frequency, referencing Cowen's opinion letter included as an annex to the proxy statement/prospectus and cited under the headings "Prospectus Summary, Opinion of Frequency's Financial Advisor" and "The Merger, Opinion of Frequency's Financial Advisor." No financial advisor to Korro Bio is identified in the facts provided. No legal advisor is identified for either party in the facts provided for this transaction. Beyond confirming that the transaction is structured as a stock-for-stock reverse merger, no further detail on the specific exchange ratio or other terms of the stock consideration is included in the facts available. Several elements of this deal remain undisclosed. The deal value is explicitly noted as not stated in the source document, and no legal advisor to either Korro Bio or Frequency Therapeutics is identified. No financial advisor to Korro Bio is named, and no expected closing date or detail on the specific exchange ratio is provided in the available material.

DiaSorin S.p.A. agreed to acquire Luminex Corporation, a Nasdaq-listed life sciences company, in a transaction announced via an 8-K press release exhibit filed by Luminex. The filing is an advisors-and-deal-terms press release confirming that a definitive agreement had been reached between the two companies. The deal is sourced from Luminex's own 8-K exhibit (filed April 12, 2021) and a later DEFM14A proxy amendment covering the fairness opinion, both of which are primary company disclosures rather than secondary reporting. The transaction proceeded to a stockholder vote process, consistent with a negotiated merger rather than an unsolicited approach. Perella Weinberg Partners acted as financial advisor to Luminex, the target, per the press release language: "Perella Weinberg Partners acted as financial advisor to Luminex Corporation and DLA Piper LLP (US) acted as legal advisor." On the acquirer side, Morgan Stanley & Co. International PLC served as DiaSorin's lead financial advisor, with Citigroup Global Markets Europe AG also advising DiaSorin and Mediobanca providing a separate fairness opinion to DiaSorin's board. DLA Piper LLP (US) served as legal advisor to Luminex. On the DiaSorin side, Cravath, Swaine & Moore LLP and Pedersoli Studio Legale (an Italian law firm, reflecting DiaSorin's Italian domicile) served as legal advisors. The source documents reviewed did not disclose an aggregate deal value, consideration mix, or expected closing date in the excerpts captured; a separate DEFM14A amendment discusses Perella Weinberg's fairness-opinion analysis and discloses approximately $3.25 million in prior unrelated capital-markets fees paid to Perella Weinberg by Luminex, but does not restate the headline transaction value. Not disclosed in the reviewed materials: the aggregate purchase price, the per-share consideration, the cash/stock mix, and the expected closing timeline. These would need to be sourced from the original January 2021 deal-announcement 8-K or the DEFM14A's summary term sheet for a complete record.

Immedica Pharma AB, a Stockholm-based global rare disease company backed by KKR and Impilo, announced on December 30, 2024 a definitive agreement to acquire Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a Radnor, Pennsylvania-based pharmaceutical company focused on seizure disorders, via a cash tender offer followed by a second-step merger. The deal gives Immedica global rights to ZTALMY (ganaxolone) oral suspension, an FDA-approved rare neurology medicine for seizures associated with CDKL5 deficiency disorder, and was structured as an all-cash transaction valuing Marinus at an implied enterprise value of approximately $151 million. This extraction is sourced from Marinus's 8-K exhibit (Exhibit 99.2) filed with the SEC on December 30, 2024, carrying the joint press release announcing the signed merger agreement. The transaction represented the culmination of a strategic alternatives review process Marinus had announced on October 24, 2024. At the time of this filing the tender offer had not yet commenced, and the deal remained subject to customary closing conditions including a majority of outstanding Marinus shares being tendered. Barclays Capital Inc. acted as Marinus's exclusive financial advisor on the sell side, while MTS Health Partners LP acted as Immedica's exclusive financial advisor on the buy side. Each bank held a sole advisory mandate for its respective party. On the legal side, Hogan Lovells LLP served as legal counsel to Marinus, while Gibson, Dunn & Crutcher LLP served as legal counsel to Immedica; Fuchs Patentanwälte Partnerschaft mbB separately served as intellectual property counsel to Immedica on the transaction. Under the terms of the agreement, Immedica, through a wholly owned subsidiary, was to commence a cash tender offer for all outstanding Marinus common stock at $0.55 per share, representing a 48% premium to Marinus's closing price as of December 27, 2024 and a 97% premium to the 30-day volume-weighted average price preceding announcement. The Marinus board unanimously approved the deal and recommended stockholders tender their shares, and each Marinus director and named executive officer undertook to tender their own shares. The transaction was expected to close in the first quarter of 2025. The press release does not disclose specific advisory fees paid to Barclays or MTS Health Partners, nor does it break out any termination fee or financing details for the all-cash tender offer beyond the aggregate enterprise value figure.

This transaction is a secondary offering of common stock by Medline Inc., trading under the ticker MDLN, classified under the equity capital markets product group. The deal is classified within the healthcare sector, and the disclosed value of the offering is 3,075,000,000 dollars. The transaction is sourced from two SEC EDGAR filings: one of unknown form type published on March 6, 2026, and a Form 424B4 prospectus also published on March 6, 2026. Based on the facts provided, the deal's status is pending regulatory approval. The underwriting syndicate for this secondary offering is structured around a group of global coordinators and joint bookrunning managers, each identified as holding lead status. Goldman Sachs & Co. LLC, Morgan Stanley, BofA Securities, and J.P. Morgan are all named as global coordinators and joint bookrunning managers for the issuer, Medline. The source material lists these four firms together repeatedly under the heading "Global Coordinators and Joint Bookrunning Managers," confirming a shared lead role across the syndicate on this offering. No legal advisor is identified for the issuer or for the underwriting syndicate in the facts provided for this transaction. Beyond confirming that this is a secondary offering of common stock with a disclosed value of 3,075,000,000 dollars, no further detail on the number of shares offered, the offering price per share, or the identity of the selling stockholders is included in the facts available. A number of elements of this deal remain undisclosed. No legal advisor to the issuer or underwriters is identified, and no detail is provided on the per-share offering price, the number of shares sold, or the identity of the selling stockholders in this secondary offering. The facts also do not specify an expected closing or settlement date.

This deal is a cash tender offer classified as an M&A transaction in the healthcare sector, involving Morphic Holding, Inc. as target and Eli Lilly and Company as acquirer. The disclosed value of the transaction is $3,200,000,000. The transaction is sourced from an 8-K filing with the SEC, filed via SEC EDGAR and published on July 8, 2024. The deal's current status is pending regulatory approval. On the financial advisory side, Centerview Partners LLC acted as exclusive financial advisor to Morphic, the target, in a lead capacity. Evercore Group L.L.C. also provided advice to Morphic, in a non-lead capacity, per a separate source sentence noting its additional advisory role. Citi acted as exclusive financial advisor to Lilly, the acquirer, in a lead capacity. On the legal side, Fenwick & West LLP acted as legal counsel, identified in the facts block under the target designation (Morphic), while Kirkland & Ellis LLP acted as legal counsel to Lilly, the acquirer. Beyond the cash consideration implied by the cash tender offer subtype, with a disclosed deal value of $3,200,000,000, no further detail on the specific per-share tender price or minimum tender condition is provided in the facts block. Several items are not disclosed in the available record. No further structural detail beyond the cash tender offer classification and disclosed value is given, and no expected closing date or further timeline detail beyond the July 2024 filing date and pending-regulatory status is provided.

Neuphoria Therapeutics Inc., a healthcare company trading under ticker NEUP, is the target in an all-share merger transaction. The acquirer has not been identified in the source materials reviewed. This is a mergers and acquisitions transaction within the healthcare sector. The transaction was announced on July 24, 2026, according to the SEC filing. The transaction details are sourced from a Form 8-K filing published on the SEC EDGAR database on July 24, 2026. The deal has been announced, meaning the parties have made the transaction public, though the current status beyond announcement (for example, whether regulatory approvals have been obtained or a closing date has been set) is not specified in the available materials. On the financial advisory side, Leerink Partners is serving as lead financial advisor to the acquirer. For the target, Neuphoria Therapeutics, two lead financial advisors have been retained: H.C. Wainwright & Co. and WG Partners LLP. Both advisors are acting in a co-lead capacity on behalf of the target company. No legal advisors are identified in the source materials provided, so the identity of counsel representing either party cannot be specified at this time. The transaction is structured as an all-share merger, meaning consideration will be paid entirely in the form of equity rather than cash or a combination thereof. Beyond this structural detail, no additional terms regarding the specific consideration mix, the exchange ratio, or other deal mechanics have been disclosed in the available documentation. Several material details remain undisclosed or unknown. Most significantly, the acquirer's identity has not been identified in the source materials. The deal value or transaction size is not stated anywhere in the filing. The expected closing date is not provided. The number of shares or exchange ratio to be used in the all-share merger is not specified. No information regarding timing to close, conditions precedent, termination provisions, or any financing arrangements is available in the materials reviewed.

Globus Medical, Inc., a musculoskeletal technology company trading under ticker GMED, agreed on February 6, 2025 to acquire Nevro Corp., a global medical device company trading under ticker NVRO that makes the HFX spinal cord stimulation platform for chronic pain, in an all-cash transaction. The deal, announced in a joint press release filed as Exhibit 99.1 to a Form 8-K, valued Nevro at approximately $250 million in total equity value, with Nevro shareholders receiving $5.85 in cash for each share of Nevro common stock. This is a cash deal, not a stock deal; the current record's reference to an all-stock structure is incorrect. The $5.85 per-share price represented a 17% premium to Nevro's February 5, 2025 closing price, a 27% premium to Nevro's 90-day volume-weighted average price of $4.61, and a 38% premium to its 30-day VWAP of $4.23, according to the companies' joint press release. Dan Scavilla, President and CEO of Globus Medical, said the transaction "furthers our mission to become the preeminent musculoskeletal technology company in the world by enabling us to expand into new markets for future growth, while gaining access to world-class, differentiated technologies that can provide significant benefit in neuromodulation, enabling technologies, and future implant solutions," adding that Globus's "scale and operational discipline will allow us to optimize Nevro's financial performance to drive enhanced profitability." Nevro CEO and President Kevin Thornal said the company was "thrilled to join Globus Medical as this will allow us to reach more patients globally with clinically proven, innovative products," citing access to "Globus Medical's capabilities, global infrastructure and other resources." The April 3, 2025 closing press release separately noted the acquisition "unlocks a $2 billion market opportunity" in neuromodulation. Nevro's board ran a broad sale process before agreeing to the deal, as described in the "Background of the Merger" section of Nevro's definitive merger proxy (DEFM14A, filed March 10, 2025). After publicly announcing a strategic review in August 2024, BofA Securities contacted 40 potential counterparties (strategic acquirers and financial sponsors); nine signed confidentiality agreements and eight participated in management presentations, referred to in the proxy as Parties A through G. All of the other named bidders ultimately declined to submit a bid or were deemed uncompetitive: a potential merger-of-equals partner (Party B), a large strategic medical device company (Party A), and four financial sponsors (Parties C, D, E and F) all withdrew between September and October 2024, and a later-contacted financial sponsor (Party G) could not provide a competitive proposal versus Globus. Globus's initial non-binding indication of interest, submitted December 4, 2024, offered $200 million in aggregate consideration (about $5.33 per share); Nevro's board rejected this as undervaluing the company. A revised Globus proposal on December 13, 2024 raised the aggregate value to $250 million, and the parties signed a letter of intent on December 20, 2024 before finalizing the $5.85 per-share Merger Agreement on February 6, 2025. BofA Securities, Nevro's financial advisor, delivered a fairness opinion dated February 5, 2025 concluding the merger consideration was fair to Nevro shareholders from a financial point of view, as disclosed in the DEFM14A. BofA Securities' selected publicly traded companies analysis (versus Avanos Medical, Orthofix Medical, Treace Medical Concepts, AngioDynamics and Inogen) applied an EV/2025E Revenue multiple range of 0.46x to 1.23x, implying a per-share equity value range of $5.35 to $12.85, versus the $5.85 deal price and Nevro's $5.13 pre-announcement closing price. A separate historical-average EV/NTM Revenue analysis applied a 0.44x to 0.80x multiple range, implying $5.15 to $8.65 per share. A discounted cash flow analysis, using Nevro management's unaudited projections (revenue growing from $421 million in 2025 to $719 million in 2033, with Adjusted EBITDA turning positive in 2028), applied discount rates of 12.00% to 14.75% and a 2.0%-3.0% perpetuity growth rate, implying $4.65 to $8.00 per share. BofA Securities also cited a 52-week trading range of $3.29 to $17.62 and analyst price targets implying a present value of $3.50 to $6.15 per share. On the financing side, Globus disclosed in its February 6, 2025 press release that it expects the Nevro acquisition to be accretive to its earnings in the second year of operation; on a standalone basis Globus had reaffirmed 2025 guidance of $2.66-$2.69 billion in net sales and $3.40-$3.50 non-GAAP EPS, while pro forma for the transaction (assuming a late-second-quarter 2025 close) it guided to $2.80-$2.90 billion in net sales and $3.10-$3.40 non-GAAP EPS, implying near-term dilution ahead of the anticipated year-two accretion. The merger agreement required Nevro, substantially concurrent with closing, to prepay in full its existing credit facility (dated November 30, 2023, with Wilmington Trust as administrative agent) and separately addressed treatment of Nevro's convertible notes, which became convertible into the cash merger consideration as reference property, and a warrant held by Braidwell Transaction Holdings LLC - Series 4, which was cashed out based on its Black-Scholes value. No new financing or pro forma ownership split is disclosed, consistent with this being a cash (not stock) acquisition. The merger agreement set a termination date of August 6, 2025, extendable to October 6, 2025 under specified conditions. Nevro was required to pay Globus a $15 million termination fee in certain circumstances, including termination to accept a superior proposal, and a separate $10 million fee if Nevro's stockholders voted down the merger; Globus was required to pay Nevro $15 million if Globus breached its obligations in a way that would prevent or materially delay closing. Closing was conditioned on Nevro stockholder approval, HSR Act clearance, and customary representations, warranties and absence of a material adverse effect. Nevro held a special stockholder meeting on April 2, 2025, at which 75.9% of outstanding shares were represented; the merger proposal was approved with 28,350,441 votes for versus 684,453 against and 90,808 abstentions, as reported in Nevro's Form 8-K (Item 5.07) filed April 2, 2025. A related non-binding advisory "golden parachute" compensation proposal did not receive the requisite vote and was not approved. The transaction closed the next day, April 3, 2025, with Palmer Merger Sub, Inc. merging into Nevro, which became a wholly owned subsidiary of Globus Medical; Nevro common stock ceased trading on the NYSE before market open that day. Each outstanding Nevro stock option was cancelled without consideration, each Nevro RSU award was converted into the right to receive cash equal to the merger consideration, and each Nevro performance-based RSU award was cashed out assuming the greater of target or actual performance. This status update (closed April 3, 2025) supersedes the "pending-regulatory" status previously on file; the deal is complete. Globus Medical's financial advisor was Morgan Stanley & Co. LLC and its legal advisor was Wyrick Robbins Yates & Ponton LLP. Nevro's financial advisor was BofA Securities, Inc. and its legal advisor was Latham & Watkins LLP, each confirmed in both the February 6, 2025 announcement press release and the April 3, 2025 closing press release.

This transaction is an acquisition, with the facts noting that the consideration structure is not specified in the excerpt available, in which Globus Medical Inc., trading under the ticker GMED, is acquiring Nevro Corp. The deal is classified within the healthcare sector, and the disclosed value of the transaction is not stated in the source document. The transaction is sourced from an SEC EDGAR Form 8-K filing published on April 3, 2025. Based on the facts provided, the deal's status is pending regulatory approval. On the financial advisory side, Morgan Stanley & Co. LLC served as financial advisor to Globus Medical, the acquirer, and is identified as the lead advisor on that side. BofA Securities, Inc. served as financial advisor to Nevro Corp., the target, and is likewise identified as the lead advisor for the target. On the legal side, Latham & Watkins LLP served as legal advisor to Nevro Corp., the target, while Wyrick Robbins Yates & Ponton LLP served as legal advisor to Globus Medical, the acquirer. As the facts explicitly note, the consideration structure for this acquisition is not specified in the excerpt available, meaning no detail on whether the transaction involves cash, stock, or a combination of the two is included in the material provided. Several elements of this deal remain undisclosed. The deal value is explicitly noted as not stated in the source document, and the consideration structure itself is explicitly flagged as not specified in the available excerpt. No expected closing date is given, and no detail on required regulatory approvals is provided in the facts available.

This transaction is a cash tender offer in which GlaxoSmithKline LLC, an affiliate of GSK plc, is seeking to acquire Nuvalent, Inc. The deal is classified within the healthcare sector, and the disclosed value of the transaction is 10,300,000,000 dollars. The transaction is sourced from an SEC EDGAR Form SC 14D9/A filing (an amendment to the Schedule 14D-9) published on July 7, 2026. Based on the facts provided, the deal's status is pending regulatory approval. On the financial advisory side, Centerview served as financial advisor to Nuvalent, the target, and is identified as the lead advisor in this transaction. The source material references an amendment adding bold and underlined language to the "Summary of Centerview Financial Analysis, Selected Public Company Analysis" discussion within the section covering the opinions of the financial advisor to the company board, indicating Centerview rendered a fairness opinion that was subsequently the subject of supplemental disclosure. No financial advisor to GlaxoSmithKline or GSK plc is identified in the facts provided. On the legal side, Ropes & Gray LLP is identified as legal advisor to Nuvalent, the target, with the source material citing the firm's Boston address at 800 Boylston Street, Prudential Tower, in a copy line for correspondence. No legal advisor to GlaxoSmithKline or GSK plc is identified in the facts provided. Beyond confirming that the transaction is structured as a cash tender offer with a disclosed value of 10,300,000,000 dollars, no further detail on the specific per-share offer price or the conditions of the tender is included in the facts available. Several elements of this deal remain undisclosed. No financial or legal advisor to GlaxoSmithKline or GSK plc is named, and no detail on the per-share tender offer price is given beyond the aggregate disclosed value. The fact that this is sourced from an amendment to the Schedule 14D-9 indicates supplemental disclosure was made, but the facts do not specify an expected closing date for the tender offer.

Quidel Corporation and Ortho Clinical Diagnostics Holdings plc announced on December 23, 2021 that they had entered into a definitive agreement for Quidel to acquire Ortho, described in the release as "one of the world's largest in vitro diagnostics companies," for $24.68 per share using a combination of cash and newly issued shares, representing a 25% premium to Ortho's prior closing price and an equity value of approximately $6.0 billion. The combined entity was expected to unite point-of-care diagnostics with Ortho's global laboratory and blood-bank footprint across more than 130 countries. This record is drawn from Quidel's Form 8-K press release exhibit dated December 23, 2021, corroborated by a May 6, 2022 Form 8-K/supplemental-disclosure filing by Ortho Clinical Diagnostics that explicitly references "Opinion of Perella Weinberg Partners LP, Arch's Financial Advisor" language adjacent to the deal's financial analyses (the supplemental filing confirms Perella Weinberg's continued role through the proxy process). At signing, the deal had unanimous board approval from both companies and was awaiting shareholder votes and regulatory clearance. On the financial advisory side, Perella Weinberg Partners LP and Citi both advised Quidel, the acquirer, with the release stating "Quidel's financial advisors in connection with this acquisition are Perella Weinberg Partners LP and Citi, and its legal advisor is Gibson, Dunn & Crutcher LLP." J.P. Morgan Securities LLC served as Ortho's sole, exclusive financial advisor, per "Ortho's exclusive financial advisor is J.P. Morgan Securities LLC, and its legal advisor is Latham & Watkins LLP," making J.P. Morgan the only named lead advisor among the group given its exclusive mandate. Legal counsel was split along the same lines: Gibson, Dunn & Crutcher LLP advised Quidel, while Latham & Watkins LLP advised Ortho. Under the terms, Ortho shareholders were to receive $7.14 in cash plus 0.1055 shares of the combined company's stock for each Ortho share, leaving Ortho holders with roughly 38% of the combined company; Quidel also assumed Ortho's existing net debt of approximately $2.0 billion. The deal was expected to close in the first half of 2022, subject to shareholder and regulatory approvals. Not disclosed in the fetched documents is a final completion date (only "first half of 2022" is given), and the precise split between the cash and stock components of the aggregate $6.0 billion headline figure beyond the per-share cash/stock mix is not broken out as an aggregate dollar split.

Outlook Therapeutics, Inc., a healthcare sector company trading under ticker OTLK, entered into an at-the-market offering agreement on May 13, 2026. This is an equity capital markets transaction with a disclosed aggregate offering price of up to $100,000,000 in common stock. The at-the-market offering structure allows the company to issue and sell shares of its common stock, par value $0.01 per share, on an opportunistic basis over time rather than in a single upfront issuance. This transaction was disclosed in an SEC filing published on May 13, 2026. While the specific form type is not definitively identified in the source materials, the legal opinion relating to the shares being offered was filed as an exhibit to a Current Report on Form 8-K, which is the typical vehicle for reporting material agreements such as at-the-market sales agreements. The deal has been announced and the sales agreement has been executed as of the filing date. No expected closing date or completion timeline has been disclosed. H.C. Wainwright & Co., LLC serves as the sales agent and/or principal in this offering and is the lead financial advisor to the issuer. The company entered into the Sales Agreement with H.C. Wainwright specifically to facilitate the issuance and sale of the common stock under the at-the-market structure. Cooley LLP serves as legal counsel to Outlook Therapeutics on this transaction, with their legal opinion regarding the validity of the shares being offered filed as an exhibit to the Form 8-K. The offering permits Outlook Therapeutics to issue and sell shares from time to time through H.C. Wainwright acting in its capacity as sales agent and/or principal. The aggregate offering price of the shares that may be issued under the Sales Agreement is up to $100,000,000. However, several material terms remain undisclosed or are inherent to the at-the-market structure itself. The actual offering price per share is not specified and will be determined by market conditions at the time of sale. The timeline for actual share issuances, the pace at which shares will be offered, any limitations on daily or other periodic issuances, and the actual amount ultimately to be raised (which may be less than the $100,000,000 maximum) have not been disclosed. Additionally, no information has been provided regarding any underwriting or sales agent commissions, any standstill or lock-up provisions, or any other material terms of the Sales Agreement beyond its basic structure and purpose.

Boston Scientific Corp, a healthcare sector company trading under ticker BSX, is acquiring Penumbra Inc (ticker PEN), also in the healthcare sector. This transaction is being structured through a leveraged finance product consisting of a revolving credit facility and a delayed draw term loan. The aggregate disclosed value of the transaction is not stated in the source documents reviewed. The information regarding this deal has been sourced from an SEC filing published on February 26, 2026, retrieved from SEC EDGAR. The specific form type is not identified in the available documentation. The deal is currently pending regulatory approval and has not yet closed. On the financial advisory side, Wells Fargo Bank, National Association has been engaged by Boston Scientific Corp, the acquirer, to serve as administrative agent for the financing arrangement. Wells Fargo holds a lead position in this capacity. No other financial advisors have been identified in the available source materials for either the borrower or the lender syndicate. No legal advisors have been identified or disclosed in the source documentation reviewed for this transaction. The deal structure comprises two credit facilities: a revolving credit facility and a delayed draw term loan. Both facilities are being provided to Boston Scientific Corp as the borrower by multiple lenders coordinated through Wells Fargo Bank, National Association in its administrative agent capacity. However, the specific terms of these facilities, including tenor, pricing, interest rate mechanics, commitment amounts, or any other quantitative details, have not been disclosed in the source documents. Several material terms and structural details remain undisclosed or unknown at this time. The aggregate transaction value is not stated in any reviewed source material. The tenor, spread, base rate, and pricing terms of both the revolving credit facility and the delayed draw term loan have not been specified. The identity of the lending syndicate members beyond the administrative agent, as well as any lead arranger or book manager roles, is not disclosed. Additionally, no expected closing date or timeline for regulatory approval has been provided. The consideration structure for the acquisition itself, including whether it is being funded entirely through these credit facilities or through other means, is not specified in the available documentation.

Bruker Corporation and PhenomeX Inc. announced on August 17, 2023 that they had signed a definitive agreement for Bruker to acquire PhenomeX for $1.00 per share in an all-cash transaction, valuing PhenomeX at a total equity value of approximately $108 million. The release describes the deal as marking "Bruker's entry into functional single-cell biology research solutions," with PhenomeX's Beacon Optofluidic platform and IsoLight/IsoSpark proteomics barcoding products complementing Bruker's spatial biology business. This record is sourced from an Exhibit 99.1 press release furnished with PhenomeX's Form 8-K filed August 17, 2023. At announcement, the transaction was a signed definitive merger agreement structured as a tender offer, not yet closed, and not subject to any financing conditions; closing was expected in the fourth quarter of 2023. Perella Weinberg Partners served as financial advisor to Bruker, the acquirer, per the release's statement "For Bruker, Perella Weinberg Partners acted as financial advisor and Morgan Lewis as legal advisor." William Blair & Company, L.L.C. served as financial advisor to PhenomeX, the target, per "For PhenomeX, William Blair & Company, L.L.C. acted as financial advisor and Freshfields Bruckhaus Deringer LLP as legal advisor." No lead designation is specified for either side since each company retained a single financial advisor. On the legal side, Morgan Lewis represented Bruker and Freshfields Bruckhaus Deringer LLP represented PhenomeX. The transaction was structured as a tender offer for all outstanding PhenomeX shares at $1.00 per share, after which PhenomeX would merge into a wholly owned Bruker subsidiary, with any untendered shares converted into the right to receive the same per-share cash consideration paid in the tender offer. Not disclosed in the sourced document is any revenue or technology-value multiple implied by the $108 million price, the number of PhenomeX instruments or customers that factored into the valuation beyond the "more than 400 instruments" installed-base figure mentioned for context, or the precise date the tender offer was expected to commence.

PMGC Holdings Inc., a healthcare sector company trading under the ticker ELAB, is conducting an at-the-market equity issuance with a disclosed aggregate offering price of $100,000,000. An at-the-market offering, or ATM, is an equity capital markets transaction that allows an issuer to sell shares into the public market opportunistically over time, typically at prevailing market prices, rather than in a single block transaction. This transaction type provides issuers with flexibility regarding the timing and volume of share sales while giving them access to capital up to a specified aggregate amount. The transaction was announced on April 24, 2025, based on documentation filed with the SEC on EDGAR. The specific SEC filing form type is not identified in the available sourcing materials. The deal is currently in announced status, though no expected closing date or timeline for share sales under the agreement has been disclosed. On the financial advisory side, Univest Securities, LLC is serving as the sales agent for the offering under the at-the-market issuance sales agreement. Univest is identified as the lead and sole financial advisor on this transaction. The sourcing materials confirm that under the terms of the agreement, PMGC Holdings may issue and sell from time to time shares of its common stock, par value $0.0001 per share, through Univest Securities in its capacity as sales agent or through any sub-agent or other designee that Univest may appoint to assist in the offering. On the legal advisory side, Sichenzia Ross Ference Carmel LLP is providing counsel to PMGC Holdings. The specific scope of their legal work is not detailed beyond their provision of an opinion related to the offering. The transaction structure provides for the issuance of common stock only. The shares are identified as having par value of $0.0001 per share. The maximum aggregate offering price across all shares that may be sold is $100,000,000. The sales agreement permits the sales agent to act through sub-agents or other designees, providing operational flexibility in the execution of share sales. Beyond these structural terms, no additional information regarding the mechanics of the offering, pricing parameters, or conditions to sales has been disclosed. Several material details regarding this offering remain undisclosed. No timeline or expected closing date for the at-the-market agreement has been provided. The specific number of shares to be issued or the anticipated pricing range has not been disclosed. The terms of Univest's compensation as sales agent are not specified in the available materials. Finally, while Sichenzia Ross Ference Carmel LLP is identified as providing legal counsel, the full scope of their engagement and any other legal advisors assisting either party have not been detailed.

Profusa, Inc., a California-incorporated clinical-stage and commercial-stage digital health company developing tissue-integrating biosensors for continuous monitoring of patient biochemistry, completed a business combination with NorthView Acquisition Corporation, a special purpose acquisition company (Nasdaq: NVAC). The transaction closed on July 11, 2025, and the combined company was renamed Profusa, Inc., with its common stock beginning trading on Nasdaq under the ticker PFSA on July 14, 2025. The merger agreement and plan of reorganization among NorthView, Profusa, and merger subsidiary NV Profusa Merger Sub Inc. was originally dated November 7, 2022 and was amended, supplemented, and modified over time before closing. NorthView shareholders approved the business combination on June 9, 2025. Under the terms of the merger agreement, each share of Profusa common stock was converted into shares of New Profusa common stock based on an exchange ratio that reflects an equity valuation of Profusa of $155,000,000, as adjusted for the Incentive Equity Value, the Private Placement Value, and the Aggregate Company Incentive Amount, divided by an assumed value of New Profusa common stock of $10.00 per share. The resulting exchange ratio was $0.94, with a Company Reference Share Value of $9.40. Immediately following closing, there were 32,788,877 shares of New Profusa common stock outstanding, no shares of preferred stock outstanding, and 17,404,250 Profusa warrants outstanding. The transaction was accounted for as a reverse capitalization under GAAP, with Profusa treated as the accounting predecessor and New Profusa as the successor SEC registrant. In connection with the closing, the combined company issued a senior secured convertible promissory note to institutional investor Ascent Partners Fund LLC, raising $9,000,000 in net proceeds (a $10,000,000 principal Initial Note at a 10% original issue discount) to fund transaction costs and working capital, under a broader PIPE facility sized up to $22,222,222 in aggregate principal ($20,000,000 aggregate purchase price). The Initial Note matures 18 months from closing, is convertible at the lower of $10.00 per share or 95% of the lowest daily VWAP in the 10 trading days prior to issuance (subject to down-round and most-favored-nation adjustments), and accrues interest at 10% per annum (24% upon default). The note is secured by substantially all assets of New Profusa and Profusa under a security agreement with Ascent as collateral agent, and is further backed by a guaranty from the Profusa parties and their subsidiaries. Certain Profusa and NorthView insiders also agreed to lock-up restrictions of six to twelve months (staged 25%/25%/50%) on Profusa-side shares, and eight months on NorthView sponsor founder shares (with early release tied to a $12.50 trading-price trigger). Ben Hwang, Ph.D., Profusa's Chairman and CEO, said: "In a journey that began over a decade ago, driven by a mission to harness transformative science to positively impact quality of daily living and chronic disease management, we are excited to mark a key milestone of going public and trading on Nasdaq. We believe being a public company better positions us to advance our vision in pioneering tissue-integrating biosensors platform that could function for months at a time, with transformative lower costs, and continuously monitor and transmit body chemistries to smart phone applications..." On the financial advisory side, A.G.P./Alliance Global Partners, I-Bankers Securities, and Dawson James Securities acted as financial advisor to NorthView Acquisition Corp. I-Bankers and Dawson James, which had been engaged under a Business Combination Marketing Agreement tied to NorthView's original IPO, received an aggregate cash fee (the Business Combination Marketing Fee) of $1,500,000 at closing, with a further $500,000 balance deferred, out of a contracted fee equal to 3.68% of NorthView's IPO gross proceeds. HCW acted as Profusa's financial advisor and received a transaction fee of $1,000,000 in cash plus 132,500 warrants to purchase New Profusa common stock at an exercise price of $0.01 per share. On legal advisors, Ellenoff Grossman & Schole LLP acted as legal advisor to Profusa, ArentFox Schiff LLP acted as legal advisor to NorthView Acquisition Corp., and Lucosky Brookman LLP acted as legal advisor to the institutional investor (Ascent Partners Fund LLC) in connection with the secured convertible promissory note. No synergy estimates, cost-saving targets, or EPS accretion/dilution figures are disclosed in the sourced filings; as a going-public reverse-merger transaction between a clinical/commercial-stage biosensor company and a non-operating SPAC shell, such metrics are not applicable in the way they would be for an operating-company-to-operating-company combination. Profusa's unaudited financials as of March 31, 2025 show a net loss of $2.7 million for the quarter (versus $2.4 million a year earlier), cash of less than $0.1 million, and notes and loans payable and interest due of $50.2 million within twelve months, with management disclosing substantial doubt about the company's ability to continue as a going concern absent additional financing. The Tasly-related party convertible debt was repaid in parallel with the closing of the business combination. The transaction has closed; it is not subject to further regulatory approval. The deal record's prior pending-regulatory status reflected an earlier gap in available source material rather than the deal's actual status, which Form 8-K filings confirm as closed as of July 11, 2025.

This transaction is a stock-for-stock merger in which Q32 Bio Inc., trading under the ticker QTTB, is combining with Homology Medicines, Inc. The deal is classified within the healthcare sector, and the disclosed value of the transaction is not stated in the source document. The transaction is sourced from an SEC EDGAR Form S-4 filing published on December 18, 2023. Based on the facts provided, the deal's status is pending regulatory approval. On the financial advisory side, Cowen and Company, LLC served as financial advisor to Homology Medicines and is identified as the lead advisor in this transaction. The source material is drawn from a consent letter dated November 15, 2023, addressed to the Board of Directors of Homology Medicines, referencing the inclusion of Cowen's opinion letter as an annex to the proxy statement/prospectus and cited under the headings "Prospectus Summary, Opinion of Homology's Financial Advisor" and "The Merger, Opinion of Homology's Financial Advisor." No financial advisor to Q32 Bio is identified in the facts provided. No legal advisor is identified for either party in the facts provided for this transaction. Beyond confirming that the transaction is structured as a stock-for-stock merger, no further detail on the specific exchange ratio or other terms of the stock consideration is included in the facts available. Several elements of this deal remain undisclosed. The deal value is explicitly noted as not stated in the source document, and no legal advisor to either Q32 Bio or Homology Medicines is identified. No financial advisor to Q32 Bio is named, and no detail on the specific exchange ratio or an expected closing date is provided in the facts available.

This is a cash acquisition via plan of arrangement in the healthcare sector in which REM Aggregator LLC is acquiring Quipt Home Medical Corp., the target. The product group is M&A. The disclosed value is not stated in the source document(s). The facts are sourced from a DEFM14A filed with the SEC via EDGAR, published on February 4, 2026. A DEFM14A is a definitive merger proxy statement, consistent with the plan-of-arrangement structure requiring shareholder approval. The deal's current status is pending regulatory review. Two financial advisors are identified on the target side, each having rendered a fairness opinion. Evans & Evans, Inc. provided a fairness opinion, as referenced by the source sentence "ANNEX D OPINION OF EVANS & EVANS, INC." Truist Securities, Inc. served as the lead financial advisor and also provided a fairness opinion, per the source sentence "ANNEX C OPINION OF TRUIST SECURITIES, INC." No financial advisor to REM Aggregator LLC, the acquirer, is identified in the facts provided. Only one legal advisor is identified in the facts block: DLA Piper (Canada) LLP, representing the target side, Quipt Home Medical Corp. The source sentence notes that "a copy of the Arrangement Agreement will also be available for inspection at the offices of DLA Piper (Canada) LLP, Suite 2700, 1133 Melville Street Vancouver, BC V6E 4E5 Canada during statutory business hours," indicating DLA Piper's role in connection with the arrangement agreement. Beyond the classification of this transaction as a cash acquisition via plan of arrangement, no further detail on the per-share cash consideration or other specific terms is included in the facts provided. Several items are not disclosed in this record: the transaction value is not stated, the per-share cash consideration is not specified, no financial or legal advisor to REM Aggregator LLC is identified, and no expected closing date is given beyond the pending-regulatory status.

GSK plc, through its subsidiary GlaxoSmithKline LLC, acquired RAPT Therapeutics, Inc. in an all-cash tender offer and second-step merger valued at an estimated aggregate equity value of $2.2 billion, or $1.9 billion net of RAPT's cash. The deal was announced on January 20, 2026 via a joint press release and was structured as a cash tender offer under the Agreement and Plan of Merger dated January 19, 2026, rather than a one-step shareholder vote merger. The transaction has since closed: GlaxoSmithKline LLC's acquisition subsidiary, Redrose Acquisition Co., completed its tender offer on March 3, 2026, with approximately 30,137,567 shares (about 93.36% of RAPT's then-outstanding shares) validly tendered, and the companies completed a back-end merger that same day under Section 251(h) of the Delaware General Corporation Law, with no RAPT stockholder vote required. RAPT now operates as a direct, wholly owned subsidiary of GlaxoSmithKline LLC. The strategic rationale centers on RAPT's lead asset, ozureprubart, a long-acting anti-IgE monoclonal antibody in Phase IIb development for prophylactic protection against food allergens. GSK's Chief Scientific Officer, Tony Wood, said: "The addition of ozureprubart brings another promising new, potential best-in-class treatment to GSK's pipeline... Ozureprubart offers the opportunity to bring sustained protection to patients with dosing every 12 weeks, and is consistent with our approach to acquire assets that address validated targets and where there is clear unmet medical need." RAPT's President and CEO, Brian Wong, said the deal "offers an attractive path forward for our programs, particularly the opportunity we envision for ozureprubart in food allergy" and would provide "access to the global development and commercialisation capabilities, resources and infrastructure that GSK has to offer." The transaction gives GSK global rights to ozureprubart excluding mainland China, Macau, Taiwan and Hong Kong; GSK assumes responsibility for success-based milestone and royalty payments owed to RAPT's China-market partner, Shanghai Jeyou Pharmaceutical Co., Ltd. Under the terms of the agreement, GSK paid $58.00 per RAPT share in cash. GSK stated the purchase price would be funded entirely with cash on hand, with no external debt financing and no financing condition attached to the offer. As a clinical-stage biopharmaceutical company with no material revenue, RAPT's valuation was assessed using a discounted cash flow analysis rather than revenue or EBITDA multiples; J.P. Morgan, the company's financial advisor, modeled unlevered free cash flows for fiscal years 2026 through 2047 based on management projections, discounted at rates of 12.0% to 14.0%, adjusted for an assumed net cash position of $390 million as of December 31, 2025, dilution from assumed future equity raises, and tax savings from net operating losses of $318 million as of December 31, 2024. This analysis produced an implied equity value range of $49.45 to $62.05 per share, which J.P. Morgan compared to the $58.00 offer price. The $58.00 per share offer price represented an approximately 65% premium to RAPT's $35.10 closing price on January 16, 2026 (the last trading day before signing), a 70% premium to the 30-day volume-weighted average price, a 97% premium to the 90-day volume-weighted average price, and a 58% premium to the highest closing price in the preceding 52 weeks. According to RAPT's Schedule 14D-9, GSK's offer progressed through three increases during negotiations: an initial non-binding proposal of $50.00 per share in cash on December 22, 2025; a revised proposal of $53.00 per share in cash plus a $4.00 per share contingent value right (CVR) tied to initiation of a pivotal Phase 3 trial of ozureprubart in food allergy by year-end 2027, submitted December 23, 2025; a further revised proposal of $55.50 per share in cash plus a CVR on December 30, 2025; and finally $58.00 per share in cash with no CVR, which RAPT's board viewed as reducing risk to stockholders relative to the earlier offers' contingent consideration. J.P. Morgan rendered a fairness opinion to RAPT's board on January 19, 2026, concluding the offer price was fair, from a financial point of view, to RAPT stockholders. Per the Schedule 14D-9's "Background of the Offer" narrative, GSK first approached RAPT in September 2025 regarding ozureprubart partnering, with discussions evolving toward an acquisition proposal by December 2025. At the board's direction, J.P. Morgan contacted eight other potential strategic counterparties to solicit competing interest; one unnamed publicly traded global pharmaceutical company ("Party A") received a management presentation but did not submit a proposal, and all others formally declined or did not respond. The board concluded GSK's $58.00 per share, all-cash offer represented the highest value reasonably obtainable and the best alternative available to stockholders, citing certainty of value, the absence of financing conditions, and the results of the market check. The merger agreement specifies a termination fee payable by RAPT to GSK of $78,400,000 under specified circumstances, such as RAPT's board changing its recommendation or accepting a superior proposal. The deal closed within the first quarter of 2026 as the parties had targeted, following a cash tender offer that commenced February 2, 2026 and expired March 2, 2026, subject to a minimum tender condition and clearance under the Hart-Scott-Rodino Antitrust Improvements Act; the original closing 8-K confirms the HSR waiting period requirement was satisfied as a condition of the merger's completion. In connection with closing, RAPT's common stock was delisted from Nasdaq and its outstanding equity awards (options, RSUs and warrants) were cancelled and converted into cash-based rights tied to the $58.00 merger consideration, with certain post-March-2025 equity grants subject to a vesting schedule (50% at closing, 50% nine months later or upon an involuntary termination, if earlier). Evercore served as exclusive financial advisor and A&O Shearman served as legal counsel to GSK. J.P. Morgan Securities LLC served as exclusive financial advisor and Cooley LLP served as legal counsel to RAPT Therapeutics.

Skye Bioscience, Inc. (Nasdaq: SKYE), a clinical-stage biotechnology company, has agreed to acquire Redx Pharma Limited, a privately held UK clinical-stage biotechnology company focused on small-molecule medicines for fibrotic disease, through a scheme of arrangement under Part 26 of the UK Companies Act 2006. The Transaction Agreement was entered into on August 14, 2026 and announced the same day in a joint press release and investor presentation filed as exhibits to a Form 8-K. Upon closing, the combined company is expected to rebrand as Fibrx Therapeutics, Inc., be led by Redx's current management team under CEO Lisa Anson, and continue trading on Nasdaq, headquartered in Alderley Park, UK. Under the Transaction Agreement, each Redx scheme share will be exchanged for Skye common stock (or, for certain electing holders, non-voting common stock convertible one-for-one into common stock) based on an Exchange Ratio tied to relative valuations set in the agreement: a valuation of $14.5 million for Skye (subject to a Company Net Cash adjustment and, if a "Specified Adjustment" is unresolved at closing, an automatic reduction to a $2.0 million valuation floor) and a valuation of $125.0 million for Redx. Skye's investor presentation separately shows a pro forma capitalization table with implied valuations of $14.5 million for Skye's 50,254,721 fully diluted shares, $161.0 million for Redx's 558,191,980 fully diluted shares (which include new Series A shares), and $89.0 million for the 325,789,219 shares tied to the concurrent financing, for total pro forma fully diluted shares outstanding of 934,235,920 and an implied combined value of approximately $264.5 million. Using this capitalization table, pre-transaction Skye holders are shown owning approximately 5.38%, Redx holders approximately 59.75%, and concurrent-financing investors approximately 34.87% of the combined company. The body of the 8-K separately describes the expected split, based on the Exchange Ratio formula and assuming $67.9 million of gross Concurrent Financing proceeds and $36.0 million of gross Series A proceeds, as approximately 5.38% for pre-transaction Skye equityholders, 46.17% for pre-transaction Redx equityholders, and 48.45% for Concurrent Financing and Series A Financing investors combined, all calculated on a fully diluted, treasury-stock-method basis and subject to adjustment based on final Company Net Cash at closing. The filings do not reconcile why the two disclosed ownership breakdowns differ, and no single, unambiguous enterprise value or EV/EBITDA-style multiple for the transaction is stated in the source documents reviewed. The deal includes concurrent financing of approximately $125 million in aggregate gross proceeds. This is composed of a $67.9 million private placement (the "Concurrent Financing" or PIPE), which may increase to up to $72.9 million under a side letter with an existing investor who agreed to invest up to an additional $5.0 million, and a separate $36.0 million Series A financing raised directly by Redx (expected to close within days of signing, subject to Redx shareholder approval) led by new investor Abingworth and including British Business Bank and Redmile. The PIPE investor syndicate includes Abingworth, British Business Bank, NextBio Capital, 5AM Ventures, and Redmile. Separately, Skye entered a binding term sheet (later finalized in a definitive Securities Purchase Agreement filed as an 8-K on August 24, 2026) with a fund affiliated with Redmile Group, LLC for a three-year committed equity line facility (ELOC) of up to $22.0 million, which will be reduced dollar-for-dollar once Concurrent Financing/Series A proceeds exceed $103.0 million and eliminated entirely if those proceeds reach $125.0 million; Skye will also issue Redmile a warrant to purchase up to $5.0 million of common and/or non-voting common stock at closing, exercisable from January 1, 2027 through January 1, 2030. Skye stated that, including proceeds from these financings, the combined company's cash is expected to fund operations into 2029 and through topline data from Redx's RXC008 Phase 2 clinical trial, expected in the second half of 2028. Quoting Redx CEO Lisa Anson in the joint press release: "This transaction gives Redx the capital and the platform to progress our pipeline and deliver the Phase 2 program for our lead asset, RXC008, a GI-restricted pan-ROCK inhibitor. We believe this is an exciting opportunity to be a leader in developing a therapeutic option for patients suffering with fibrostenotic Crohn's disease, considered by many to be one of the largest unmet medical needs in IBD..." Skye President and CEO Punit Dhillon stated: "Over the last several months, Skye has evaluated a wide range of options to maximize shareholder value, including an assessment of our internal pipeline, financing opportunities and strategic alternatives... We believe this transaction provides our shareholders a compelling opportunity to realize both short- and long-term value creation through Redx's novel anti-fibrotic therapies, led by their first-in-class pan-ROCK inhibitor, RXC008." The investor presentation adds that Skye discontinued its CBeyond Phase 2a trial for lead asset nimacimab and paused its development in the second quarter of 2026 after reviewing the evolving anti-obesity drug landscape, and engaged a financial advisor to evaluate strategic alternatives before agreeing to the Redx transaction, which the company describes as "a capital decision not a biology conclusion." As part of the transaction structure, pre-transaction Skye shareholders will receive one contingent value right (CVR) per share entitling them, in aggregate, to 90% of any net cash proceeds realized from monetization of Skye's legacy nimacimab program and associated intellectual property during the 12-month period following closing. Certain pre-transaction Redx shareholders will separately receive one CVR per Redx ordinary share entitling them to 100% of net proceeds, paid in Fibrx shares, from monetization of certain Redx legacy and partnered assets during the 15 years following closing. Additionally, Skye's board approved a 1-for-8 reverse stock split of its common stock, effective August 24, 2026, undertaken to regain compliance with Nasdaq's $1.00 minimum bid price requirement; a subsequent 8-K dated September 11, 2026 confirmed that Nasdaq notified Skye it had regained compliance after 10 consecutive trading days at or above $1.00. On the advisory side, Stifel is acting as exclusive financial advisor to Skye on the strategic transaction, with Morrison & Foerster LLP serving as Skye's legal counsel. Wedbush PacGrow is acting as exclusive financial advisor to Redx, with Cooley LLP serving as Redx's legal counsel. In the PIPE Financing, Leerink Partners and MTS Health Partners are acting as placement agents, with MTS Health Partners acting as exclusive placement agent for the separate Series A Financing; Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. is advising the placement agents as legal counsel. The transaction is subject to numerous closing conditions, including approval by Redx shareholders of the scheme of arrangement, sanction of the scheme by the High Court of Justice of England and Wales, approval by Skye stockholders of the share issuance and related matters (including a possible reverse stock split and articles amendments), receipt of at least $67.9 million in Concurrent Financing proceeds, Nasdaq listing approval for the new shares, and a minimum Company Net Cash threshold of at least $1.0 million at closing. If the "Specified Adjustment" referenced in the agreement has not been resolved by a certain date, closing cannot occur before October 31, 2026. Voting and support agreements covering approximately 83.34% of Redx's outstanding share capital and approximately 1.05% of Skye's voting power have been signed in favor of the transaction, and certain Redx executives and directors signed 180-day lock-up agreements. The agreement includes reciprocal termination fees: either party can be required to pay the other an amount equal to 3% of the combined company's valuation (including the Concurrent Financing purchase price) under specified circumstances, including a change in board recommendation, failure to obtain required shareholder approvals combined with a competing proposal, or acceptance of a superior proposal. The Transaction Agreement also provides for automatic termination if the deal has not closed by August 14, 2027 (with up to a four-business-day extension in limited circumstances). The press release states the companies expect to close the transaction in the fourth quarter of 2026, subject to these conditions; no closing 8-K, vote-result 8-K, or merger proxy statement (PREM14A/DEFM14A) had been filed as of the filings reviewed, so the deal remains pending and unconsummated based on available information.

Sangamo Therapeutics, Inc., trading under ticker SGMOQ, is the subject of a bankruptcy asset sale within the healthcare sector. This restructuring transaction, classified as a product group matter, involves the sale of assets with a disclosed transaction value of 263.55 million USD. The transaction information is sourced from an SEC filing published on the SEC EDGAR platform on August 13, 2026. While the specific form type is not identified in the available materials, the filing represents the primary disclosure document for this matter. The deal's current status is pending regulatory approval or clearance. Sangamo Therapeutics has retained a comprehensive advisory team across financial and legal disciplines. On the financial side, the company engaged MERU, LLC to serve as its financial advisor, and Raymond James to serve as its restructuring banker. These advisors are working in tandem to manage the financial and restructuring aspects of the asset sale process. The company's legal counsel consists of two firms: Cooley LLP and Richards, Layton & Finger, PA, both of which are representing Sangamo in the transaction. No additional information regarding specific deal terms, consideration structure, or the identity of the acquiring party or parties has been disclosed in the available materials. The transaction timeline, including any expected closing date, has not been specified. Similarly, no details regarding the composition of the assets being sold, any earn-out provisions, assumed liabilities, or other material transaction structure elements have been made public. The 263.55 million USD valuation represents the sole quantitative metric disclosed for this restructuring transaction.

This deal is an unsolicited take-private proposal structured as a management buyout, in which Seer, Inc. (ticker SEER), a company in the healthcare sector, is the target of a proposal involving Dr. Omid Farokhzad, M.D. The transaction is classified under the M&A product group, and the disclosed deal value is not stated in the source document. The facts block is sourced from a single SEC filing: an 8-K filed with SEC EDGAR and published on July 2, 2026. The deal's current status is pending regulatory approval. On the financial advisory side, Perella Weinberg Partners LP is serving as financial advisor to Seer, the target, with no lead designation specified in the facts block. No financial advisor is disclosed for the proposing party (Dr. Farokhzad) in the facts block. Legal counsel was disclosed only for the target: Wilson Sonsini Goodrich & Rosati, Professional Corporation is serving as legal counsel to Seer. No legal advisor is disclosed for the proposing party. Beyond its characterization as an unsolicited take-private proposal structured as a management buyout, the facts block provides no further detail on proposed consideration, pricing, or financing structure. Several material facts are not disclosed in the source material. The overall proposed deal value is not stated. No financial or legal advisor is named for the proposing party, Dr. Omid Farokhzad. The facts block also does not disclose an expected timeline, proposed price per share, or whether the Seer board has responded to or accepted the unsolicited proposal.

This record concerns an unsolicited take-private proposal, which was rejected, in the healthcare sector, involving Seer, Inc. (ticker SEER) as the target and the Radoff/JEC Group, consisting of Bradley L. Radoff and Michael Torok, as the proposing party. The product group is M&A. The disclosed value is not stated in the source document(s). The facts are sourced from an 8-K filed with the SEC via EDGAR, published on May 22, 2026. The deal's current status is pending regulatory review, notwithstanding that the proposal itself is described as having been rejected. Only one financial advisor is identified in the facts block: Perella Weinberg Partners LP, serving as financial advisor to Seer, the target. The source sentence states: "Perella Weinberg Partners LP is serving as financial advisor to Seer, and Wilson Sonsini Goodrich & Rosati, Professional Corporation is serving as legal counsel." No lead designation is specified, and no financial advisor to the Radoff/JEC Group is identified in the facts provided. One legal advisor is identified: Wilson Sonsini Goodrich & Rosati, Professional Corporation, serving as legal counsel to Seer, the target, per the same source sentence. No legal advisor to the Radoff/JEC Group is identified in the facts provided. Beyond the classification of this matter as an unsolicited take-private proposal that was rejected, no further detail on the proposed consideration, valuation, or other specific terms of the Radoff/JEC Group's proposal is included in the facts provided. Several items are not disclosed in this record: the proposed transaction value and consideration terms are not stated, no financial or legal advisor to the Radoff/JEC Group is identified, and no further detail on the basis for rejection or subsequent timeline is given beyond the pending-regulatory status field and the characterization of the proposal as rejected.

Select Medical Holdings Corporation, a Mechanicsburg, Pennsylvania-based operator of critical illness recovery hospitals, rehabilitation hospitals and outpatient rehabilitation clinics, announced the completion of its going-private acquisition on July 1, 2026. The buyer was a consortium led by Robert A. Ortenzio (Select Medical's Executive Chairman and Co-Founder), Martin F. Jackson (a senior Select Medical executive), and private equity firm Welsh, Carson, Anderson & Stowe (WCAS). The transaction was structured under an Agreement and Plan of Merger dated March 2, 2026, and the healthcare services company valued the deal at approximately $3.9 billion based on a purchase price of $16.50 per share, an 18% premium to the unaffected share price. This extraction is drawn from Select Medical's 8-K press release exhibit announcing deal completion, filed with the SEC on July 1, 2026. Because the buying group included company insiders (Ortenzio and Jackson) alongside the sponsor, the Company's Board of Directors formed a Special Committee of disinterested, independent directors to evaluate the transaction, and stockholders including unaffiliated holders voted to approve it at a June 26, 2026 special meeting. Barclays served as financial advisor to WCAS, the private equity sponsor in the consortium, alongside legal counsel Ropes & Gray LLP. On the other sides of the transaction, Goldman Sachs served as exclusive financial advisor to the Special Committee of independent directors, and Wells Fargo and J.P. Morgan served as financial advisors to the broader Consortium (with J.P. Morgan and Wells Fargo also acting as joint lead arrangers and bookrunners on the committed debt financing). Legal counsel included Skadden, Arps, Slate, Meagher & Flom LLP for the Special Committee, Dechert LLP for Select Medical itself, Cravath, Swaine & Moore LLP for the Consortium, and Paul Hastings LLP for the debt financing sources, in addition to Ropes & Gray LLP representing WCAS. Upon closing, the Consortium obtained effective and operational control along with a majority economic interest in Select Medical, and the company's common stock ceased trading on the New York Stock Exchange. Existing management, including Ortenzio and Jackson, was to continue leading the business in their current roles. The press release does not disclose the specific allocation of debt versus equity financing within the $3.9 billion transaction value, the individual fees paid to Barclays or any other advisor, or the precise ownership split among Ortenzio, Jackson, and WCAS within the Consortium following closing.

Singular Genomics Systems, Inc. (Nasdaq: OMIC), a San Diego-based life science technology company developing next-generation sequencing and spatial multiomics platforms, entered into an Agreement and Plan of Merger on December 22, 2024 with Singular Genomics Parent, LLC and its wholly owned subsidiary Saturn Merger Sub, Inc. Parent and Merger Sub are newly formed entities affiliated with Deerfield Private Design Fund IV, L.P., an investment fund managed by Deerfield Management Company, L.P. that was already a shareholder of the company. The transaction was announced publicly on December 23, 2024 and the merger closed on February 21, 2025, with Singular Genomics becoming a wholly owned subsidiary of the Deerfield-affiliated Parent. Under the terms of the merger agreement, each share of Singular Genomics common stock and Series A Common Stock Equivalent Convertible Preferred Stock (the latter held entirely by Deerfield) not held by Deerfield or other rollover stockholders was cancelled and converted into the right to receive $20.00 in cash per share, without interest. The company's announcement press release stated that the $20.00 per share price represented a 254% premium to the last closing share price prior to the September 12, 2024 public disclosure of Deerfield's initial acquisition proposal. Deerfield and certain other stockholders entered into Rollover Agreements under which their shares, RSUs, or options were contributed to Parent in exchange for equity in Parent rather than cash consideration. With only approximately 2,537,024 shares of common stock outstanding and entitled to vote as of the January 10, 2025 record date, the implied common equity value of the publicly held shares subject to the cash consideration was well under $50 million; the deal's enterprise value is not disclosed in the filings reviewed. The transaction was not subject to a financing condition. Parent secured committed debt financing from Deerfield to fund the merger consideration. At closing, Deerfield Private Design Fund IV entered into a Credit Agreement with Parent and Merger Sub as borrowers, committing to provide a term loan of up to $37.5 million; approximately $37 million of proceeds were deposited with the paying agent to fund payments to stockholders. The loan bears interest at 8%, matures February 20, 2026, and is prepayable at any time. Singular Genomics became a borrower under the Credit Agreement as the surviving corporation. The Singular Genomics Board of Directors formed a special committee composed entirely of independent and disinterested directors to evaluate the company's strategic alternatives. The special committee led negotiations with the assistance of independent financial and legal advisors and unanimously recommended that the board approve the merger agreement, which the full board then did following that recommendation. TD Securities and Houlihan Lokey served as financial advisors to the special committee. Gunderson Dettmer LLP served as legal advisor to Singular Genomics, Richards, Layton & Finger, P.A. served as counsel to the special committee, and Katten Muchin Rosenman LLP served as legal advisor to Deerfield. Andrew ElBardissi, M.D., Partner at Deerfield, said in the announcement press release: "Singular Genomics has developed a state-of-the-art multi-omic spatial biology platform that empowers customers with innovative tools to unlock biological insights and drive breakthroughs in research and medicine. We are proud to support Singular Genomics as they embark on this exciting new chapter, advancing science and serving their customers with excellence." The company stated that becoming a private company would provide Singular Genomics with greater flexibility to continue advancing its business strategy. The merger agreement contained customary termination rights. If terminated by the company under specified circumstances, including entry into a superior proposal or a change in the board's recommendation, the company would owe Parent a termination fee of $1,520,246. The company would also owe this fee if the merger failed to close by the April 22, 2025 Outside Date under certain conditions, if a third-party acquisition proposal for at least 50% of the company's stock or assets was publicly announced and not withdrawn, if stockholders failed to approve the deal, or if the company later entered into or consummated such a third-party proposal within one year of termination. Parent's aggregate monetary liability for willful and material breach or fraud was capped at $2,533,744, a damages cap backstopped by a Limited Guarantee from Deerfield. Separately, Support Agreements were signed concurrently with the merger agreement by stockholders Andrew Spaventa, Eli Glezer, Dalen Meeter, Mike Pellini, and David Barker, who beneficially owned approximately 8.4%, 6.7%, 0.8%, 0.7%, and 1.6%, respectively, of the company's outstanding voting power, committing them to vote in favor of the merger. The merger was approved at a special stockholder meeting held February 19, 2025. Of approximately 2,028,305 shares present or represented by proxy (about 80.0% of shares entitled to vote, constituting a quorum), 2,023,327 shares voted in favor, 3,933 voted against, and 1,045 abstained, representing overwhelming approval. The merger closed two days later, on February 21, 2025. Trading in Singular Genomics common stock was suspended on Nasdaq as of the close of trading that day, the company notified Nasdaq of its intent to delist, and the company indicated it would file a Form 15 to deregister its common stock and suspend its Exchange Act reporting obligations. Following closing, Josh Stahl was appointed Chief Executive Officer of Singular Genomics and joined its board, Jason Myers also joined the board, and Drew Spaventa, the company's co-founder and former CEO and Chairman, remained on the board and took on an additional role as special advisor to the new CEO. The filings reviewed do not disclose an EV/EBITDA, P/E, or other earnings-based valuation multiple for the transaction, nor do they disclose synergy targets, pro forma combined financial projections, or details of the negotiation background (such as other bidders considered) beyond confirming that a special committee process took place; that detail may appear in the DEFM14A proxy statement's "Background of the Merger" section, which was not reviewed as part of this update beyond what is cited above.

This is a stock-for-stock merger in the healthcare sector in which Standard BioTools Inc. (ticker LAB) is the acquirer of SomaLogic, Inc. The product group is M&A. The disclosed value is not stated in the source document(s). The facts are sourced from an S-4 registration statement filed with the SEC via EDGAR, published on November 14, 2023. An S-4 is the filing type used to register securities issued in connection with a merger, consistent with the stock-for-stock structure of this deal. The current status of the transaction is pending regulatory review. Perella Weinberg Partners L.P. is identified as the lead financial advisor to SomaLogic, the target. The source sentence is a consent letter excerpt stating: "We hereby consent to the inclusion of our opinion dated October 4, 2023 appearing as Annex C to, and the reference to such opinion letter under the headings 'Prospectus Summary, Opinion of SomaLogic's Financial Advisor' and 'The Merger, Opinion of SomaLogic Financial Advisor' in, the Registration Statement on Form S-4 of Standard BioTools Inc. and in the Joint Proxy Statement/Prospectus of Standard BioTools Inc. and SomaLogic, Inc." This confirms Perella Weinberg's role included rendering a fairness opinion to SomaLogic dated October 4, 2023. No financial advisor to Standard BioTools, the acquirer, is identified in the facts provided. No legal advisors were extracted for this transaction in the available facts block. Beyond the classification of this transaction as a stock-for-stock merger, no further detail on the exchange ratio or other specific consideration terms is included in the facts provided. Several items are not disclosed in this record: the transaction value is not stated, no financial advisor to the acquirer is identified, no legal advisors to either side are identified, the exchange ratio is not specified, and no expected closing date is given beyond the pending-regulatory status.

Sunshine Biopharma Inc., a healthcare sector company trading under ticker SBFM on the Nasdaq Capital Market, entered into an At-The-Market Issuance Sales Agreement with Aegis Capital Corp. on July 20, 2026, under which the company may sell shares of common stock having an aggregate offering price of up to $4,000,000 from time to time through Aegis as its exclusive sales agent. The agreement was disclosed in a Form 8-K filed that day and in a prospectus supplement on Form 424B5, filed the same date under the company's effective Form S-3 shelf registration statement (File No. 333-284142, declared effective January 15, 2025). The ATM is structured as a continuous, uncommitted offering rather than a single priced block trade. Aegis is not required to sell any specific number or dollar amount of shares and will act on a commercially reasonable efforts basis; the company is not obligated to sell, and Aegis is not obligated to buy or sell, any shares. Sales may be made directly on or through Nasdaq or any other existing trading market for the stock, with the company delivering placement notices to Aegis specifying the number of shares, timing, and any minimum sale price for each tranche. Because there is no minimum offering amount, the prospectus supplement states the actual total public offering amount, commissions, and net proceeds to the company could not be determined at the time of filing. Aegis will receive a fixed cash commission equal to 3.0% of gross proceeds on each sale made under the agreement, plus reimbursement of certain expenses, and will be deemed an "underwriter" under the Securities Act with respect to that compensation. The prospectus supplement discloses that the last reported Nasdaq sale price of SBFM common stock on July 17, 2026 (the last trading day before the prospectus supplement date) was $1.80 per share; no separate per-share ATM pricing or discount to that price is specified, consistent with the program's at-the-market, variable-price structure. The stock had undergone a 10-for-1 reverse stock split effective June 1, 2026. The company stated it intends to use net proceeds from the offering for general corporate purposes, including working capital, with no specific allocation (such as debt repayment or acquisition financing) identified; management was given broad discretion over use of proceeds. No greenshoe or over-allotment option applies, as is typical for ATM programs, and none is mentioned in the filings. Sunshine Biopharma's Form 10-Q for the quarter ended June 30, 2026 (filed August 13, 2026) discloses, as a subsequent event, that from July 27, 2026 through August 12, 2026 -- roughly one week after signing through the quarter's filing date -- the company sold 1,430,521 shares of common stock under the ATM Offering and received $1,722,555 in net proceeds, equating to roughly $1.20 per share net of the 3.0% commission. The same disclosure notes that on August 3, 2026 the company's outstanding Series B Warrants were adjusted to 25,477,133 warrants with a $1.2202 exercise price as an anti-dilution consequence of the ATM share sales. As of August 13, 2026, the company had 3,877,337 shares of common stock issued and outstanding, which includes the ATM shares sold to that date; the 10-Q does not break out what percentage of shares outstanding the ATM sales alone represented, and no concurrent share repurchase program is disclosed. On the legal side, Hart & Hart, LLC (Denver, Colorado) acted as counsel to the issuer on the validity of the shares, delivering an opinion dated July 20, 2026 and filed as Exhibit 5.1 to the Form 8-K, consenting also to its reference under "Legal Matters" in the prospectus supplement. The prospectus supplement additionally identifies Sichenzia Ross Ference Carmel LLP, New York, as issuer's counsel on U.S. federal securities and New York state law matters, and Kaufman & Canoles, P.C., Richmond, Virginia, as counsel to Aegis Capital Corp. (the sales agent) in connection with the offering. The consolidated financial statements incorporated by reference were audited by M&K CPAs, PLLC. No closing 8-K, termination notice, or filing indicating the $4,000,000 ATM capacity has been fully utilized or the program has been terminated was identified. Given that active, ongoing sales under the program were confirmed as of the August 13, 2026 10-Q, the deal is best treated as an open, in-progress ATM program rather than a single dated closing; status is left as announced/ongoing pending any filing disclosing full utilization or termination of the Sales Agreement.

This deal involves GTCR acquiring Surmodics Inc, a healthcare-sector company, in a cash acquisition structured as a take-private by a private equity sponsor. The transaction is classified under the M&A product group and carries a disclosed value of $627,000,000. The deal remains in pending regulatory status. The facts underlying this summary come from an SEC EDGAR Form 8-K filed and published on May 29, 2024. No other source documents are referenced in the available record. On the advisory side, Goldman Sachs & Co. LLC served as financial advisor to GTCR, the acquirer, in a lead capacity, working alongside Kirkland & Ellis LLP and Cleary Gottlieb Steen & Hamilton LLP, which together provided legal counsel to GTCR. For Surmodics, the target, Jefferies LLC served as financial advisor in a lead role, while Faegre Drinker Biddle & Reath LLP provided legal counsel to the company. Legal representation breaks down cleanly by side: Kirkland & Ellis LLP and Cleary Gottlieb Steen & Hamilton LLP represented the acquirer, GTCR, while Faegre Drinker Biddle & Reath LLP represented the target, Surmodics. Beyond the cash consideration and the take-private structure implied by the subtype label, the facts block does not provide further detail on the specific per-share price, financing sources, or any contingent consideration elements that may be part of the agreement. A number of details are not disclosed in the available record. No expected closing date is given. No information is provided about financing commitments or termination fees. The facts block also does not specify what approvals are outstanding under the pending-regulatory status.

Aveanna Healthcare Holdings Inc., a home care services company trading under ticker AVAH, agreed to acquire Thrive Skilled Pediatric Care, LLC ("Thrive SPC"), a portfolio company backed by growth investment firm Summit Partners. The agreement was announced on April 3, 2025, in a press release attached to a current report on Form 8-K, which disclosed that Aveanna would pay approximately $75.0 million for Thrive SPC, primarily in shares of its common stock, subject to customary purchase price adjustments. The transaction closed on June 2, 2025, roughly two months after signing. Thrive SPC is one of the largest independent providers of pediatric home care, operating 23 locations across seven states: Arizona, Georgia, Kansas, New Mexico, North Carolina, Virginia, and Texas. It primarily provides skilled Private Duty Nursing services, along with Pediatric Therapy, Licensed Health Aide Services, and Certified Nurse Assistant Services. Aveanna said the combination creates an enhanced footprint in states where it already operates while introducing its care model into two new states. Jeff Shaner, Chief Executive Officer of Aveanna, said in the announcement: "Thrive SPC is an exceptional cultural and geographical fit for us and reinforces our strategic mission of remaining the leader in delivering high quality care while bringing unprecedented value and clinical innovation to our payors and stakeholders." Ross Stern, a Managing Director at Summit Partners, said: "We believe Aveanna is an ideal partner for Thrive SPC, given the combined company's shared vision for delivering the highest quality care to patients and innovative and cost-effective solutions to its payors." According to Aveanna's Form 10-Q for the quarter ended June 28, 2025, the company paid approximately $75.7 million in total consideration at closing on June 2, 2025, comprising $15.855 million in cash and $59.838 million in share-based consideration, consisting of 11,184,588 shares of common stock (approximately 11.2 million shares) valued at the opening market price on the closing date. Approximately 1.3 million of the issued shares were placed in escrow for up to 12 months following closing to support indemnification and other obligations under the merger agreement. The shares were issued in a private placement exempt from registration under Section 4(a)(2) of the Securities Act. The 10-Q disclosed a preliminary purchase price allocation: total identifiable net assets acquired of $11.515 million (including $5.0 million of license intangibles and $0.54 million of trade name intangibles, net of assumed liabilities such as accrued payroll and other current liabilities), against total consideration of $75.693 million, resulting in preliminary goodwill of $64.178 million. Aveanna stated that goodwill is primarily attributable to expected synergies from the acquisition, though no specific dollar synergy target or phase-in timeline was disclosed. All of the goodwill was allocated to Aveanna's Private Duty Services (PDS) segment. Aveanna explicitly stated that pro forma financial information for the acquisition was not provided because it was not material to the company's consolidated results of operations, and that Thrive's results were not significant for the six-month period ended June 28, 2025. The company also recorded $3.4 million of acquisition-related transaction costs in the second quarter of 2025 ($3.5 million for the six-month period), which were cited as a drag on corporate expenses in that period. Edge Healthcare Partners served as financial advisor to Aveanna, and Bass, Berry & Sims provided legal counsel to Aveanna. Cantor Fitzgerald & Co. served as financial advisor to Thrive SPC, while Ropes & Gray LLP served as Thrive SPC's legal advisor. The transaction has closed. No earnout, exchange ratio, EV/EBITDA multiple, financing-related new debt issuance, or EPS accretion/dilution guidance was disclosed in the filings reviewed. The merger agreement itself (dated April 1, 2025) was not filed as an exhibit to any 8-K reviewed, so its specific termination fee, closing conditions, and other negotiated deal terms beyond the price and advisor disclosures above remain non-public.

This deal is a cash and stock acquisition classified as an M&A transaction in the healthcare sector, involving Thrive Skilled Pediatric Care LLC (Thrive SPC) as target and Aveanna Healthcare Holdings, Inc. (ticker AVAH) as acquirer. The disclosed value of the transaction is $75,000,000. The transaction is sourced from an 8-K filing with the SEC, filed via SEC EDGAR and published on April 3, 2025. The deal's current status is pending regulatory approval. On the financial advisory side, Cantor Fitzgerald & Co. served as financial advisor to Thrive SPC, the target, in a lead capacity. Edge Healthcare Partners served as financial advisor to Aveanna, the acquirer, also in a lead capacity, with the source material pairing each advisor with its respective legal counsel. On the legal side, Ropes & Gray LLP served as legal advisor to Thrive SPC, the target, while Bass, Berry & Sims provided legal counsel to Aveanna, the acquirer. Beyond the cash and stock consideration structure noted in the deal subtype, with a disclosed value of $75,000,000, no further detail on the specific split between cash and stock components, or other structural terms, is provided in the facts block. Several items are not disclosed in the available record. The precise cash-versus-stock consideration mix is not broken out beyond the general subtype classification, and no expected closing date or further timeline detail beyond the April 2025 filing date and pending-regulatory status is given.

Ligand Pharmaceuticals Inc., a publicly traded healthcare company trading under the ticker LGND, is acquiring XOMA Royalty Corp., a healthcare sector target, in a merger and acquisition transaction. The deal carries a disclosed value of $739 million in USD. Both the acquirer and target operate in the healthcare sector, and the transaction was announced as of the filing date. This transaction was disclosed through an SEC Form 8-K filing published on July 14, 2026, which serves as the primary source document for deal information. The deal has been announced, indicating that the parties have publicly confirmed the transaction, though no closing date or other timeline milestones have been disclosed. On the acquirer side, Ligand Pharmaceuticals engaged Stifel as its lead financial advisor. Supporting Ligand's transaction efforts, Citi also served as a financial advisor to the acquirer. On the target side, XOMA Royalty Corp. retained Leerink Partners as a lead financial advisor and H.C. Wainwright & Co. as an additional financial advisor, ensuring that XOMA had dual representation throughout the transaction process. No legal advisors have been disclosed in the available transaction documents. The transaction is structured as a merger and acquisition in the healthcare sector. The total consideration is valued at $739 million; however, the specific composition of the consideration, whether paid in cash, stock, or a combination thereof, has not been disclosed. Similarly, the precise structure of the merger, including details about merger subsidiary structures or any earnout provisions, has not been publicly detailed in the available filings. Key details that remain undisclosed include the expected closing date and timing, the breakdown of consideration by type and payment method, any financing arrangements or conditions precedent, material terms specific to the merger structure, and details regarding any regulatory filings or approvals that may be required. The sources do not specify whether any debt financing, equity financing, or other transaction financing has been arranged.

This transaction is a cash acquisition with a contingent value right in which Ligand Pharmaceuticals Incorporated, trading under the ticker LGND, is acquiring XOMA Royalty Corp. The deal is classified within the healthcare sector, and the disclosed value of the transaction is 739,000,000 dollars. The transaction is sourced from an SEC EDGAR Form 8-K filing published on July 14, 2026. Based on the facts provided, the deal's status is pending regulatory approval. On the financial advisory side, Leerink Partners served as lead financial advisor to XOMA Royalty, the target, with H.C. Wainwright & Co. also serving as a financial advisor to XOMA Royalty in a supporting, non-lead capacity. On the acquirer side, Stifel served as lead financial advisor to Ligand, with Citi also serving as a financial advisor to Ligand, and the source material additionally notes that Collected Strategies served as strategic communications advisor to Ligand, rounding out the acquirer's advisory team. On the legal side, Gibson, Dunn & Crutcher LLP served as legal advisor to XOMA Royalty, the target, while Paul Hastings LLP served as legal advisor to Ligand, the acquirer. Beyond confirming that this is a cash acquisition structured with a contingent value right and a disclosed value of 739,000,000 dollars, no further detail on the specific cash amount per share, the CVR terms, or the milestones triggering any CVR payout is included in the facts available. Several elements of this deal remain undisclosed. No specific per-share cash price or CVR payout terms are given beyond the aggregate disclosed value of 739,000,000 dollars, and no expected closing date is provided. The facts also do not specify what regulatory approvals are required to complete the transaction.

SERB Pharmaceuticals ("SERB"), a global specialty pharmaceutical company focused on rare diseases and medical emergencies, agreed to acquire Y-mAbs Therapeutics, Inc. (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on antibody-based cancer therapeutics, in an all-cash tender offer and merger. The deal was announced August 5, 2025 via a definitive merger agreement dated August 4, 2025, filed as Exhibit 2.1 to Y-mAbs' Form 8-K. The transaction has closed: SERB's wholly owned subsidiary Yosemite Merger Sub, Inc. completed its tender offer on September 15, 2025, with approximately 39,827,138 shares (about 87.22% of shares outstanding) validly tendered, and the companies completed a short-form merger under Section 251(h) of the Delaware General Corporation Law on September 16, 2025, with Y-mAbs becoming a wholly owned subsidiary of SERB's acquisition vehicle, Perseus BidCo US, Inc. Y-mAbs shares were delisted from Nasdaq effective September 16, 2025. SERB paid $8.60 per share in cash for all outstanding Y-mAbs common stock, representing an equity value of approximately $412 million as announced and aggregate consideration (including option and restricted stock unit cashouts) of approximately $413 million, which Parent funded through a combination of cash on hand and short-term financing. The offer price represented an approximately 105% premium to Y-mAbs' closing share price of $4.19 on August 4, 2025, the last full trading day before the merger agreement was signed, and an approximately 92% premium to the volume-weighted average price of Y-mAbs shares over the 90 trading days ending August 4, 2025. Y-mAbs' financial advisor, Centerview Partners, performed a discounted cash flow analysis using discount rates of 14.5% to 16.5%, cash flows from July 1, 2025 through December 31, 2050, a terminal decline rate of 20% per year, and credit for approximately $240 million of federal and $194 million of state net operating losses as of December 31, 2024, net of the estimated cost of assumed future equity raises of $75 million in 2026, $50 million in 2027, $100 million in 2028, $100 million in 2029, and $150 million in a later year per management's financing assumptions. Strategic rationale focused on Y-mAbs' lead commercial asset DANYELZA (naxitamab-gqgk), the first FDA-approved treatment for relapsed or refractory high-risk neuroblastoma. SERB CEO Vanessa Wolfeler stated, "High-risk neuroblastoma is not only a rare and devastating pediatric cancer but also one of the most difficult to treat. DANYELZA is recognized as a critical treatment option for patients and expands the treatment pathways available to providers in an outpatient setting. Working together with the team from Y-mAbs, I believe we can continue generating data for this product, expand partnerships to additional oncology centers, and have a positive impact on the lives of more neuroblastoma patients and their families." SERB Chairman Jeremie Urbain said the acquisition "reflects another milestone in the execution of our growth strategy to build a leading global specialty pharma platform" and that "DANYELZA is an excellent strategic fit for SERB as it strengthens our existing rare oncology portfolio." Y-mAbs CEO Michael Rossi said the agreement with SERB "reflects the most attractive option available to Y-mAbs, providing significant, immediate and certain value to our stockholders," following what the Schedule 14D-9 describes as a roughly five-month strategic review in which Y-mAbs or Centerview contacted or held discussions with at least 36 potential counterparties, signed confidentiality agreements with six potential strategic acquirers and five potential RIT investors, and received competing offers from two counterparties (referred to in the filing as Party A through Party H) before SERB emerged as the only party willing to proceed on acceptable terms. The merger agreement provided for a termination fee payable by Y-mAbs of $14.25 million, equal to approximately 3.46% of the implied equity value of the transaction, in the event Y-mAbs terminated to accept a superior proposal or under other specified circumstances. Y-mAbs stockholders holding approximately 16% of outstanding shares signed tender and support agreements committing to tender their shares. Closing was conditioned on a majority of outstanding shares being tendered and expiration or termination of the HSR Act antitrust waiting period; SERB was contractually obligated to commence the tender offer by August 19, 2025, and the companies had targeted a close by the fourth quarter of 2025, though the transaction in fact closed September 16, 2025, ahead of that target. Y-mAbs agreed to pay Centerview an aggregate fee of approximately $9.1 million for its financial advisory services, of which $1.5 million was payable upon delivery of its fairness opinion and the remainder contingent on closing. Y-mAbs retained Centerview Partners as exclusive financial advisor, Cooley LLP as legal counsel, and Joele Frank, Wilkinson Brimmer Katcher as strategic communications advisor. SERB retained Rothschild & Co. as exclusive financial advisor, Freshfields US LLP as legal counsel, and H/Advisors Abernathy as strategic communications advisor. At the effective time, outstanding Y-mAbs stock options with exercise prices below $8.60 were cancelled and converted into the right to receive cash equal to the spread, out-of-the-money options were cancelled for no consideration, and restricted stock units and performance stock units were cancelled and converted into cash based on the $8.60 merger consideration (with PSUs cashed out at maximum share levels). Following the merger, all of Y-mAbs' incumbent directors (Thomas Gad, David N. Gill, Laura J. Hamill, James I. Healy, Michael Rossi, Ashutosh Tyagi and Johan Wedell-Wedellsborg) and several executive officers, including CEO Michael Rossi, resigned in connection with the transaction.

This transaction is a follow-on common stock offering by Zentalis Pharmaceuticals, Inc. (ticker ZNTL), a healthcare sector company. The offering falls under the equity capital markets (ECM) product group and carries a disclosed value of $95,450,000. The deal is currently in pending regulatory status. This summary is sourced from an SEC EDGAR Form 424B5 filed and published on August 14, 2026. The offering involved a syndicate of financial advisors in differentiated roles, all on the issuer side. TD Cowen, Guggenheim Securities, and Oppenheimer & Co. are each named as joint bookrunners in a lead capacity, per the source sentence listing the joint bookrunners as TD Cowen, Guggenheim Securities, and Oppenheimer & Co. H.C. Wainwright & Co. served in the distinct role of passive bookrunner, a non-lead capacity, while Rodman & Renshaw LLC served simply as manager, also non-lead. No legal advisors are identified in the facts block for this transaction. As a follow-on common stock offering, this transaction involves the sale of additional shares by an already-public issuer, but the facts block does not disclose the number of shares offered, the offering price per share, or any underwriters' over-allotment option terms. Several material facts remain undisclosed. No legal advisors are named for the issuer or the underwriting syndicate. No expected closing date is given beyond the filing date, and no detail is provided on share count, price per share, or use of proceeds.

This deal is an asset/product-line acquisition classified as an M&A transaction in the healthcare sector, involving Zoetis's medicated feed additive (MFA) product portfolio as the divested assets and Phibro Animal Health Corp (ticker PAHC) as acquirer. The disclosed value of the transaction is $350,000,000. The transaction is sourced from an 8-K filing with the SEC, filed via SEC EDGAR and published on April 29, 2024. The deal's current status is pending regulatory approval. On the financial advisory side, Guggenheim Securities, LLC acted as exclusive financial advisor to Zoetis, the target/divesting party, in a lead capacity. Citi acted as exclusive financial advisor to Phibro, the acquirer, also in a lead capacity, per the respective source sentences pairing each financial advisor with its legal counsel. On the legal side, Wachtell, Lipton, Rosen & Katz acted as legal advisor to Zoetis, the target, while Kirkland & Ellis LLP acted as legal advisor to Phibro, the acquirer. Beyond the asset/product-line acquisition structure, with a disclosed deal value of $350,000,000, no further detail on which specific products within the MFA portfolio are included or excluded, or other structural terms, is provided in the facts block. Several items are not disclosed in the available record. No further detail on the specific scope of the MFA product portfolio transferred is given beyond the general description, and no expected closing date or further timeline detail beyond the April 2024 filing date and pending-regulatory status is provided.

Zynex Inc, a healthcare sector company, is the subject of a Chapter 11 reorganization proceeding. This is a restructuring transaction, specifically a bankruptcy reorganization under Chapter 11 of the U.S. Bankruptcy Code. The transaction involves the formal restructuring of the company's capital structure and operations through the bankruptcy process. No transaction value has been disclosed in the available source documents. The information regarding this deal is sourced from an SEC filing published on the SEC EDGAR platform on March 20, 2026. The specific form type associated with this filing was not identified in the source materials. The deal is currently in pending regulatory status, indicating that the Chapter 11 reorganization is active but has not yet reached completion or emergence from bankruptcy protection. No financial advisors have been identified as advising either the debtor or other parties involved in this Chapter 11 reorganization based on the available source materials. This absence of disclosed financial advisory representation may reflect that either no such advisors were retained, or their engagement has not yet been publicly disclosed through the SEC filings examined. No legal advisors have been identified in the available source materials for this transaction. The deal structure and specific terms of the reorganization have not been disclosed in the source documents reviewed. This includes information about the treatment of claims, any proposed reorganization plan, the capital structure of the reorganized entity, or any other material terms that would typically be outlined in Chapter 11 bankruptcy documentation. Several material details remain unknown or undisclosed at this stage. The transaction value is not stated anywhere in the source materials. The specific reorganization plan terms are not disclosed. No expected emergence or closing date has been provided. The identity of equity or debt holders, the treatment of various classes of claims, and any proposed financing for the reorganization have all not been disclosed in the available filings. Additionally, while the form type was not specified in the source materials, it is unclear whether this comes from an initial Chapter 11 petition, a disclosure statement, a plan of reorganization, or other bankruptcy court filings, which would materially affect the level of detail available regarding the transaction structure.